

Barb only please!

68691

Access DB#

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Dwayne Jones Examiner # 71299 Date: 12 JUN 02  
Art Unit: 1614 Phone Number 30 8-4634 Serial Number: 091579, 564  
Mail Box and Bldg/Room Location: 2007, CM1 Results Format Preferred (circle): PAPER DISK E-MAIL  
2001/CM1

If more than one search is submitted, please prioritize searches in order of need.  
\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see attached sheet

Inventors (please provide full names):

Earliest Priority Filing Date: 000 73 AUG 1991

*For Sequence Searches Only\** Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search James Ward  
JS

Shank

Point of Contact:  
Barb O'Brien  
Technical Information Specialist  
STIC CM1 6A05 308-4291

STAFF USE ONLY

Searcher: <u>BOB</u>	Type of Search	Vendors and cost where applicable
Searcher Phone #:	NA Sequence (#)	STN <u>390</u>
Searcher Location:	AA Sequence (#)	Dialog
Date Searcher Picked Up:	Structure (#) <u>2</u>	Questel/Orbit
Date Completed: <u>6-24-02</u>	Bibliographic	Dr.Link
Searcher Prep & Review Time: <u>50</u>	Litigation	Lexis/Nexis
Clerical Prep Time:	Fulltext	Sequence Systems
Online Time: <u>53</u>	Patent Family	WWW/Internet
	Other	Other (specify)

---

**THIS PAGE BLANK (USPTO)**

=> fil reg; d stat que 139  
FILE 'REGISTRY' ENTERED AT 15:27:17 ON 24 JUN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 22 JUN 2002 HIGHEST RN 433282-38-3  
DICTIONARY FILE UPDATES: 22 JUN 2002 HIGHEST RN 433282-38-3


TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L18 SCR 1126 AND 1597  
L28 STR








VAR G1=34/35/36/24/38/48  
NODE ATTRIBUTES:  
CONNECT IS E1 RC AT 10  
CONNECT IS E2 RC AT 38  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 48

STEREO ATTRIBUTES: NONE  
L31 1365 SEA FILE=REGISTRY SSS FUL L28 AND L18

L37

STR



*subset search done  
on this structure  
(species of claim 85)*

VAR G1=48/49

VAR G2=56/61

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 49

DEFAULT MLEVEL IS ATOM

GGCAT IS MCY LOC SAT AT 49

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE

L39 6 SEA FILE=REGISTRY SUB=L31 SSS FUL L37

100.0% PROCESSED 492 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.02

=&gt; fil capl;d que nos 140; d que nos 141

FILE 'CAPLUS' ENTERED AT 15:27:30 ON 24 JUN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jun 2002 VOL 136 ISS 26  
FILE LAST UPDATED: 21 Jun 2002 (20020621/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L18 SCR 1126 AND 1597  
L28 STR  
L31 1365 SEA FILE=REGISTRY SSS FUL L28 AND L18  
L37 STR  
L39 6 SEA FILE=REGISTRY SUB=L31 SSS FUL L37  
L40 5 SEA FILE=CAPLUS ABB=ON L39

L18 SCR 1126 AND 1597  
L28 STR  
L31 1365 SEA FILE=REGISTRY SSS FUL L28 AND L18  
L37 STR  
L39 6 SEA FILE=REGISTRY SUB=L31 SSS FUL L37  
L41 5 SEA FILE=USPATFULL ABB=ON L39

=> dup rem 140,141

FILE 'CAPLUS' ENTERED AT 15:27:36 ON 24 JUN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)


FILE 'USPATFULL' ENTERED AT 15:27:36 ON 24 JUN 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)  
PROCESSING COMPLETED FOR L40  
PROCESSING COMPLETED FOR L41  
L43 5 DUP REM L40 L41 (5 DUPLICATES REMOVED)  
ANSWERS '1-5' FROM FILE CAPLUS

=> d ibib abs hitstr 143 1-5; fil cao; d que nos 142

L43 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1  
ACCESSION NUMBER: 2001:241760 CAPLUS  
DOCUMENT NUMBER: 134:280612  
TITLE: Preparation of 1-arylethylamines as calcium receptor ligands  
INVENTOR(S): Van Wagenen, Bradford C.; Moe, Scott T.; Balandrin, Manuel F.; Delmar, Eric G.; Nemeth, Edward F.  
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA  
SOURCE: U.S., 142 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

-----  
 US 6211244      B1    20010403      US 1995-546998      19951023  
 OTHER SOURCE(S):      MARPAT 134:280612  
 GI



AB Title compds., e.g., I [R = H or alkyl; R1,R2 = (un)substituted Ph or naphthyl; Z = (CH2)0-3] were prepd. Thus, (R)-1-(1-naphthyl)ethylamine was condensed with 2-acetonaphthone to give I (R = Me, R1 = 2-naphthyl, R2 = 1-naphthyl, Z = bond). Data for biol. activity of title compds. were given.


IT **199734-46-8P 332078-10-1P 332078-11-2P**  
**332078-12-3P 332078-23-6P 332078-54-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 1-arylethylamines as calcium receptor ligands)

RN 199734-46-8 CAPLUS

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-(4-phenylcyclohexyl)-, [N(R)]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 332078-10-1 CAPLUS

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-(4-phenylcyclohexyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 332078-11-2 CAPLUS

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-(3-phenylcyclohexyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 332078-12-3 CAPLUS

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-(3-phenylcyclohexyl)-,  
(.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 332078-23-6 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R,2S)-2-phenylcyclopropyl]-,  
rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332078-54-3 CAPLUS

CN 1-Naphthalenemethanamine, N-[cyclopropyl(4-methoxyphenyl)methyl]-.alpha.-  
methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

229 THERE ARE 229 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L43 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2  
 ACCESSION NUMBER: 2000:10638 CAPLUS  
 DOCUMENT NUMBER: 132:88193  
 TITLE: Ion receptor- and calcium receptor-active molecules,  
 receptor proteins, nucleic acids encoding them,  
 anti-receptor antibodies, and uses  
 INVENTOR(S): Nemeth, Edward F.; Van Wagenen, Bradford C.;  
 Balandrin, Manuel F.; Delmar, Eric G.; Moe, Scott T.  
 PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA  
 SOURCE: U.S., 191 pp., Cont.-in-part of Appl. No.  
 PCT/US94/12117.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 9  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6011068	A	20000104	US 1994-353784	19941208
JP 09281209	A2	19971031	JP 1996-232165	19920821
JP 09328420	A2	19971222	JP 1996-232130	19920821
JP 11221095	A2	19990817	JP 1998-313631	19920821
JP 3256502	B2	20020212		
JP 2001220356	A2	20010814	JP 2000-394979	19920821
CN 1071333	A	19930428	CN 1992-111580	19920822
CN 1067550	B	20010627		
IL 102917	A1	20001206	IL 1992-102917	19920823
ZA 9206360	A	19930330	ZA 1992-6360	19920824
CA 2173747	AA	19950427	CA 1994-2173747	19941021
WO 9511221	A1	19950427	WO 1994-US12117	19941021
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9480872	A1	19950508	AU 1994-80872	19941021
AU 702629	B2	19990225		
EP 724561	A1	19960807	EP 1994-931982	19941021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1139917	A	19970108	CN 1994-194577	19941021
JP 09504032	T2	19970422	JP 1994-512244	19941021
US 6001884	A	19991214	US 1995-469204	19950606
US 5688938	A	19971118	US 1995-485588	19950607
US 5763569	A	19980609	US 1995-484565	19950607
US 5858684	A	19990112	US 1995-480751	19950607
US 6031003	A	20000229	US 1995-484719	19950607
US 6313146	B1	20011106	US 1995-484159	19950607
CA 2202879	AA	19960502	CA 1995-2202879	19951023
WO 9612697	A2	19960502	WO 1995-US13704	19951023
WO 9612697	A3	19960613		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9641957	A1	19960515	AU 1996-41957	19951023
AU 709303	B2	19990826		
EP 787122	A2	19970806	EP 1995-940547	19951023



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE  
BR 9509411 A 19971230 BR 1995-9411 19951023  
JP 10513436 T2 19981222 JP 1996-514118 19951023  
JP 2882882 B2 19990412  
HU 77980 A2 19990201 HU 1998-2491 19951023  
JP 11130737 A2 19990518 JP 1998-16563 19951023  
CN 1220658 A 19990623 CN 1995-197005 19951023  
EP 1203761 A2 20020508 EP 2001-204920 19951023  
EP 1203761 A3 20020515

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE  
AU 9671977 A1 19970220 AU 1996-71977 19961125  
AU 711247 B2 19991007  
US 5962314 A 19991005 US 1997-943986 19971003  
AU 9931226 A1 19990722 AU 1999-31226 19990524

PRIORITY APPLN. INFO.:

US 1991-749451 B2 19910823  
US 1992-834044 B2 19920211  
US 1992-934161 B2 19920821  
US 1993-17127 B2 19930212  
US 1993-9389 B2 19930223  
US 1993-141248 B2 19931022  
US 1994-292827 B2 19940819  
WO 1994-US12117 A2 19941021  
JP 1992-504650 A3 19920821  
JP 1996-232165 A3 19920821  
JP 1998-313631 A3 19920821  
AU 1994-80872 A3 19941021  
US 1994-353784 A2 19941208  
US 1995-484565 A1 19950607  
EP 1995-940547 A3 19951023  
JP 1996-514118 A3 19951023  
WO 1995-US13704 W 19951023

OTHER SOURCE(S): MARPAT 132:88193

AB The invention relates to the different roles inorg. ion receptors have in cellular and body processes. The invention features: (1) mols. which can modulate one or more inorg. ion receptor activities, preferably the mol. can mimic or block an effect of an extracellular ion on a cell having an inorg. ion receptor, more preferably the extracellular ion is Ca<sup>2+</sup> and the effect is on a cell having a calcium receptor; (2) inorg. ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorg. ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorg. ion receptor proteins, preferably calcium receptor protein; and (5) uses of such mols., proteins, nucleic acids and antibodies.

IT **199734-46-8**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ion receptor- and calcium receptor-active mols., receptor proteins, nucleic acids encoding them, anti-receptor antibodies, and uses)

RN 199734-46-8 CAPLUS

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-(4-phenylcyclohexyl)-, [N(R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3  
ACCESSION NUMBER: 1999:45055 CAPLUS  
DOCUMENT NUMBER: 130:119576  
TITLE: Whole-cell assays and expression systems for calcium receptor genes and their use in screening for effectors of calcium receptors  
INVENTOR(S): Nemeth, Edward F.; Brown, Edward M.; Hebert, Steven C.; Garrett, James E., Jr.; Van Wagenen, Bradford C.; Balandrin, Manuel F.; Del Mar, Eric G.  
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA; NPS Pharmaceuticals, Inc.  
SOURCE: U.S., 176 pp. Cont.-in-part of U.S. Ser. No. 353,784. CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 9  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5858684	A	19990112	US 1995-480751	19950607
JP 09281209	A2	19971031	JP 1996-232165	19920821
JP 09328420	A2	19971222	JP 1996-232130	19920821
JP 11221095	A2	19990817	JP 1998-313631	19920821
JP 3256502	B2	20020212		
JP 2001220356	A2	20010814	JP 2000-394979	19920821
CN 1071333	A	19930428	CN 1992-111580	19920822
CN 1067550	B	20010627		
IL 102917	A1	20001206	IL 1992-102917	19920823
ZA 9206360	A	19930330	ZA 1992-6360	19920824
CA 2173747	AA	19950427	CA 1994-2173747	19941021
CN 1139917	A	19970108	CN 1994-194577	19941021
US 6011068	A	20000104	US 1994-353784	19941208
AU 9671977	A1	19970220	AU 1996-71977	19961125
AU 711247	B2	19991007		
AU 9931226	A1	19990722	AU 1999-31226	19990524
PRIORITY APPLN. INFO.:			US 1991-749451	B2 19910823
			US 1992-834044	B2 19920211
			US 1992-934161	B2 19920821
			US 1993-17127	B2 19930212
			US 1993-9389	B2 19930223
			US 1993-141248	B2 19931022
			US 1994-292827	B2 19940819
			US 1994-353784	A2 19941208
			JP 1992-504650	A3 19920821
			JP 1996-232165	A3 19920821
			JP 1998-313631	A3 19920821
			AU 1994-80872	A3 19941021
			WO 1994-US12117	A2 19941021

OTHER SOURCE(S): MARPAT 130:119576

AB Methods for screening for drugs that act on receptors for inorg. ions, specifically  $\text{Ca}^{2+}$ , that can be used in the treatment of diseases assocd. with abnormalities of inorg. ion homeostasis are described. Xenopus oocytes are used to synthesize receptors from injected mRNA and the effects of drugs tested, e.g. electrophysiol. Parathyroid cells and osteoclasts can be used to measure the ability of the drug to affect parathyroid hormone secretion. Calcium receptor subtypes could be differentiated pharmacol. Lead compds. were identified for the design of effectors of several subtypes of the receptor. One of these compds. was shown to lower serum ionized calcium when administered orally to rats. Cloning of cDNAs for calcium receptors of cattle and human tissue is demonstrated. Use of one of the cattle clones to identify a rat inorg. ion receptor cDNA is also described.


IT 199734-46-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(effects on cytosolic calcium responses of; whole-cell assays and expression systems for calcium receptor genes and their use in screening for effectors of calcium receptors)

RN 199734-46-8 CAPLUS

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-(4-phenylcyclohexyl)-, [N(R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS

DUPLICATE 4

ACCESSION NUMBER: 1998:405442 CAPLUS

DOCUMENT NUMBER: 129:49631

TITLE: Cloning and cDNA sequences of mammalian calcium receptors and their use in screening for compounds with potential action in the therapy of disorders of calcium metabolism

INVENTOR(S): Brown, Edward M.; Hebert, Steven C.; Garrett, James E., Jr.

PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc, USA; NPS Pharmaceuticals, Inc.

SOURCE: U.S., 174 pp., Cont.-in-part of U.S. Ser. No. 353,784. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5763569	A	19980609	US 1995-484565	19950607
JP 09281209	A2	19971031	JP 1996-232165	19920821
JP 09328420	A2	19971222	JP 1996-232130	19920821
JP 11221095	A2	19990817	JP 1998-313631	19920821

JP 3256502	B2	20020212		
JP 2001220356	A2	20010814	JP 2000-394979	19920821
CN 1071333	A	19930428	CN 1992-111580	19920822
CN 1067550	B	20010627		
IL 102917	A1	20001206	IL 1992-102917	19920823
ZA 9206360	A	19930330	ZA 1992-6360	19920824
CA 2173747	AA	19950427	CA 1994-2173747	19941021
CN 1139917	A	19970108	CN 1994-194577	19941021
US 6011068	A	20000104	US 1994-353784	19941208
AU 9671977	A1	19970220	AU 1996-71977	19961125
AU 711247	B2	19991007		
US 5962314	A	19991005	US 1997-943986	19971003
AU 9931226	A1	19990722	AU 1999-31226	19990524

PRIORITY APPLN. INFO.:

US 1991-749451	B2	19910823
US 1992-834044	B2	19920211
US 1992-934161	B2	19920821
US 1993-17127	B2	19930212
US 1993-9389	B2	19930223
US 1993-141248	B2	19931022
US 1994-292827	B2	19940819
US 1994-353784	A2	19941208
JP 1992-504650	A3	19920821
JP 1996-232165	A3	19920821
JP 1998-313631	A3	19920821
AU 1994-80872	A3	19941021
WO 1994-US12117	A2	19941021
US 1995-484565	A1	19950607

OTHER SOURCE(S): MARPAT 129:49631

AB The present invention relates to the different roles inorg. ion receptors have in cellular and body processes. The present invention features: (1) ~~mol.s. which can modulate one or more inorg. ion receptor activities,~~ preferably the mol. can mimic or block an effect of an extracellular ion on a cell having an inorg. ion receptor, more preferably the extracellular ion is Ca<sup>2+</sup> and the effect is on a cell having a calcium receptor; (2) inorg. ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorg. ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorg. ion receptor proteins, preferably calcium receptor protein; and (5) uses of such mols., proteins, nucleic acids, and antibodies. Thus, calcium receptor cDNAs were cloned and sequences from various mammalian sources, including cattle (BoPCaR1), human (phPCaR-5.2 and phPCaR-4.0), and rat kidney (RaKCaR). Novel compds. useful in these methods and compns. as calcimimetics or calcilytics are also provided. Such compds include arylalkylamines such as substituted R-phenylpropyl-1-phenylethylamines, substituted R-benzyl-.alpha.-phenethylamines, and substituted R-benzyl-.alpha.-1-naphthylethylamine analogs. Preferably, the mol. is able to act as either a selective agonist or antagonist at a Ca<sup>2+</sup> receptor of one or more but not all cells chosen from a group consisting of parathyroid cells, bone osteoclasts, parafollicular cells in the thyroid (C-cells), and Xenopus oocytes.

IT 199734-46-8


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cloning and cDNA sequences of mammalian calcium receptors and their use in screening for compds. with potential action in the therapy of disorders of calcium metab.)

RN 199734-46-8 CAPLUS

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-(4-phenylcyclohexyl)-, [N(R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L43 ANSWER 5 OF '5 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 5  
 ACCESSION NUMBER: 1997:761612 CAPLUS  
 DOCUMENT NUMBER: 128:30379  
 TITLE: Cloning and cDNA sequences of mammalian calcium receptors and their use in screening for compounds with potential action in the therapy of disorders of calcium metabolism  
 INVENTOR(S): Brown, Edward M.; Fuller, Forrest H.; Hebert, Steven C.; ~~Garrett, James E., Jr~~  
 PATENT ASSIGNEE(S): Brigham & Women's Hospital, Inc., USA; NPS Pharmaceuticals, Inc.  
 SOURCE: U.S., 174 pp., Cont.-in-part of U.S. Ser. No. 353,784. CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 9  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US <del>5688938</del>	A	19971118	US 1995-485588	19950607
JP 09281209	A2	19971031	<del>JP 1996-232165</del>	<del>19920821</del>
JP 09328420	A2	19971222	JP 1996-232130	19920821
JP 11221095	A2	19990817	JP 1998-313631	19920821
JP 3256502	B2	20020212		
JP 2001220356	A2	20010814	JP 2000-394979	19920821
CN 1071333	A	19930428	CN 1992-111580	19920822
CN 1067550	B	20010627		
IL 102917	A1	20001206	IL 1992-102917	19920823
ZA 9206360	A	19930330	ZA 1992-6360	19920824
CA 2173747	AA	19950427	CA 1994-2173747	19941021
CN 1139917	A	19970108	CN 1994-194577	19941021
US 6011068	A	20000104	US 1994-353784	19941208
AU 9671977	A1	19970220	AU 1996-71977	19961125
AU 711247	B2	19991007		
AU 9931226	A1	19990722	AU 1999-31226	19990524
PRIORITY APPLN. INFO.:			US 1991-749451	B2 19910823
			US 1992-834044	B2 19920211
			US 1992-934161	B2 19920821
			US 1993-17127	B2 19930212
			US 1993-9389	B2 19930223
			US 1993-141248	B2 19931022
			US 1994-292827	B2 19940819
			US 1994-353784	A2 19941208
			JP 1992-504650	A3 19920821
			JP 1996-232165	A3 19920821
			JP 1998-313631	A3 19920821
			AU 1994-80872	A3 19941021
			WO 1994-US12117	A2 19941021

AB The present invention relates to the different roles inorg. ion receptors have in cellular and body processes. The present invention features: (1)

mols. which can modulate one or more inorg. ion receptor activities, preferably the mol. can mimic or block an effect of an extracellular ion on a cell having an inorg. ion receptor, more preferably the extracellular ion is  $\text{Ca}^{2+}$  and the effect is on a cell having a calcium receptor; (2) inorg. ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorg. ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorg. ion receptor proteins, preferably calcium receptor protein; and (5) uses of such mols., proteins, nucleic acids, and antibodies. Thus, calcium receptor cDNAs were cloned and sequences from various mammalian sources, including cattle (BoPCaR1), human (phPCaR-5.2 and phPCaR-4.0), and rat kidney (RaKCaR). Novel compds. useful in these methods and compns. as calcimimetics or calcilytics are also provided. Such compds include arylalkylamines such as substituted R-phenylpropyl-1-phenylethylamines, substituted R-benzyl-.alpha.-phenethylamines, and substituted R-benzyl-.alpha.-1-naphthylethylamine analogs. Preferably, the mol. is able to act as either a selective agonist or antagonist at a  $\text{Ca}^{2+}$  receptor of one or more but not all cells chosen from a group consisting of parathyroid cells, bone osteoclasts, parafollicular cells in the thyroid (C-cells), and *Xenopus* oocytes.

IT 199734-46-8


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cloning and cDNA sequences of mammalian calcium receptors and their use in screening for compds. with potential action in the therapy of disorders of calcium metab.)

RN 199734-46-8 CAPLUS

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-(4-phenylcyclohexyl)-, [N(R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



FILE 'CAOLD' ENTERED AT 15:27:53 ON 24 JUN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of

all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L18 SCR 1126 AND 1597  
L28 STR  
L31 1365 SEA FILE=REGISTRY SSS FUL L28 AND L18  
L37 STR  
L39 6 SEA FILE=REGISTRY SUB=L31 SSS FUL L37  
L42 0 SEA FILE=CAOLD ABB=ON L39

=> fil reg; d stat que l31

FILE 'REGISTRY' ENTERED AT 15:29:20 ON 24 JUN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 22 JUN 2002 HIGHEST RN 433282-38-3

DICTIONARY FILE UPDATES: 22 JUN 2002 HIGHEST RN 433282-38-3

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:


<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L18


SCR 1126 AND 1597

L28

STR



*same full file  
search as before*



VAR G1=34/35/36/24/38/48

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 10

CONNECT IS E2 RC AT 38

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 48

STEREO ATTRIBUTES: NONE



L31 1365 SEA FILE=REGISTRY SSS FUL L28 AND L18

100.0% PROCESSED 59462 ITERATIONS  
SEARCH TIME: 00.00.07

1365 ANSWERS

=> fil capl; d que nos 135  
FILE 'CAPLUS' ENTERED AT 15:29:29 ON 24 JUN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jun 2002 VOL 136 ISS 26  
FILE LAST UPDATED: 21 Jun 2002 (20020621/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L18 SCR 1126 AND 1597  
L28 STR  
L31 1365 SEA FILE=REGISTRY SSS FUL L28 AND L18  
L32 17758 SEA FILE=CAPLUS ABB=ON CALCIUM(L)RECEPTOR#/OBI  
L33 862 SEA FILE=CAPLUS ABB=ON L31  
L35 22 SEA FILE=CAPLUS ABB=ON L33 (L) L32

=> s 135 not 140

L44 17 L35 NOT L40 *previously printed*

=> fil uspatf; d que nos 148; s 148 not 141  
FILE 'USPATFULL' ENTERED AT 15:31:36 ON 24 JUN 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 20 Jun 2002 (20020620/PD)  
FILE LAST UPDATED: 20 Jun 2002 (20020620/ED)  
HIGHEST GRANTED PATENT NUMBER: US6408437  
HIGHEST APPLICATION PUBLICATION NUMBER: US2002078483  
CA INDEXING IS CURRENT THROUGH 20 Jun 2002 (20020620/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 20 Jun 2002 (20020620/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2002  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2002

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<

>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> <<<  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

L18 SCR 1126 AND 1597  
L28 STR  
L31 1365 SEA FILE=REGISTRY SSS FUL L28 AND L18  
L45 520 SEA FILE=REGISTRY ABB=ON L31 AND USPATFULL/LC  
L46 135 SEA FILE=USPATFULL ABB=ON L45  
L47 842 SEA FILE=USPATFULL ABB=ON CALCIUM(3A)RECEPTOR#  
L48 18 SEA FILE=USPATFULL ABB=ON L46 AND L47

L52 13 L48 NOT L41

*previously  
printed*

=> dup rem 144,152

FILE 'CAPLUS' ENTERED AT 15:31:47 ON 24 JUN 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:31:47 ON 24 JUN 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)  
PROCESSING COMPLETED FOR L44  
PROCESSING COMPLETED FOR L52

L53 26 DUP REM L44 L52 (4 DUPLICATES REMOVED)  
ANSWERS '1-17' FROM FILE CAPLUS  
ANSWERS '18-26' FROM FILE USPATFULL

=> d ibib abs hitstr 153 1-26; fil hom

L53 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1  
ACCESSION NUMBER: 2001:810328 CAPLUS  
DOCUMENT NUMBER: 135:352750  
TITLE: Calcium receptor-active molecules  
INVENTOR(S): Van Wagenen, Bradford C.; Balandrin, Manuel F.;  
Delmar, Eric G.; Nemeth, Edward F.  
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA  
SOURCE: U.S., 227 pp., Cont.-in-part of U.S. Ser. No. 353,784.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 9  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6313146	B1	20011106	US 1995-484159	19950607
JP 09281209	A2	19971031	JP 1996-232165	19920821
JP 09328420	A2	19971222	JP 1996-232130	19920821
JP 11221095	A2	19990817	JP 1998-313631	19920821
JP 3256502	B2	20020212		
JP 2001220356	A2	20010814	JP 2000-394979	19920821
CN 1071333	A	19930428	CN 1992-111580	19920822
CN 1067550	B	20010627		
IL 102917	A1	20001206	IL 1992-102917	19920823
ZA 9206360	A	19930330	ZA 1992-6360	19920824
CA 2173747	AA	19950427	CA 1994-2173747	19941021
WO 9511221	A1	19950427	WO 1994-US12117	19941021
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9480872	A1	19950508	AU 1994-80872	19941021
AU 702629	B2	19990225		
EP 724561	A1	19960807	EP 1994-931982	19941021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1139917	A	19970108	CN 1994-194577	19941021
JP 09504032	T2	19970422	JP 1994-512244	19941021
US 6011068	A	20000104	US 1994-353784	19941208
AU 9671977	A1	19970220	AU 1996-71977	19961125
AU 711247	B2	19991007		
AU 9931226	A1	19990722	AU 1999-31226	19990524
PRIORITY APPLN. INFO.:				
			US 1991-749451	B2 19910823
			US 1992-834044	B2 19920211
			US 1992-934161	A2 19920821
			US 1993-17127	B2 19930212
			US 1993-9389	B2 19930223
			US 1993-141248	B2 19931022
			US 1994-292827	B2 19940819
			WO 1994-US12117	A2 19941021
			US 1994-353784	A2 19941208
			JP 1992-504650	A3 19920821
			JP 1996-232165	A3 19920821
			JP 1998-313631	A3 19920821
			AU 1994-80872	A3 19941021

OTHER SOURCE(S): MARPAT 135:352750

AB The present invention relates to the different roles inorg. ion receptors have in cellular and body processes. The present invention features: (1) mols. which can modulate one or more inorg. ion receptor activities, preferably the mol. can mimic or block an effect of an extracellular ion on a cell having an inorg. ion receptor, more preferably the extracellular ion is Ca<sup>2+</sup> and the effect is on a cell having a calcium receptor; (2) inorg. ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorg. ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorg. ion receptor proteins, preferably calcium receptor protein; and (5) uses of such mols., proteins, nucleic acids and antibodies.

IT 148717-54-8, NPS R-568 148717-56-0, NPS R-467

159149-76-5 179603-37-3 199614-68-1

199615-26-4 199615-27-5 199615-29-7

226256-47-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(calcium receptor-active mols. for pharmaceutical use)

RN 148717-54-8 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 148717-56-0 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159149-76-5 CAPLUS

CN Benzenepropanamine, 3-fluoro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179603-37-3 CAPLUS

CN Benzenepropanamine, 3-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199614-68-1 CAPLUS

CN Benzenepropanamine, 4-fluoro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-26-4 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-27-5 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-29-7 CAPLUS


CN Benzenepropanamine, 2-fluoro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226256-47-9 CAPLUS  
 CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-3-(trifluoromethoxy)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 179381-53-4P 179381-55-6P 179381-59-0P  
 179381-61-4P 179381-63-6P 179381-65-8P  
 179381-66-9P 179381-68-1P 179381-70-5P  
 252055-41-7P 259855-86-2P 259855-87-3P  
 RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL  
 (Biological study); PREP (Preparation); USES (Uses)  
 (calcium receptor-active mols. for pharmaceutical  
 use)  
 RN 179381-53-4 CAPLUS  
 CN 1-Naphthalenemethanamine, .alpha.-methyl-N-(3-phenylpropyl)- (9CI) (CA  
 INDEX NAME)



RN 179381-55-6 CAPLUS  
 CN Benzenepropanamine, 2-methoxy-N-[(1R)-1-(3-methoxyphenyl)ethyl]-,  
 hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● HCl

RN 179381-59-0 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[[4-(1-methylethyl)phenyl]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 179381-61-4 CAPLUS  
CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 179381-63-6 CAPLUS  
CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 179381-65-8 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxyphenyl)ethyl]-.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 179381-66-9 CAPLUS

CN 1-Naphthalenemethanamine, N-[(3-chloro-4-methoxyphenyl)methyl]-.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 179381-68-1 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)ethyl]-



.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 179381-70-5 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(3-chloro-4-methoxyphenyl)ethyl]-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-41-7 CAPLUS


CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-(2-naphthalenyl)ethyl]-  
, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 259855-86-2 CAPLUS  
CN Benzenepropanamine, N-[1-[3-(methylthio)phenyl]ethyl]-, hydrochloride  
(9CI) (CA INDEX NAME)



● HCl

RN 259855-87-3 CAPLUS  
CN 1-Naphthalenemethanamine, N-[3-(2-chlorophenyl)propyl]-.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


REFERENCE COUNT: 202 THERE ARE 202 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L53 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2  
ACCESSION NUMBER: 2000:381465 CAPLUS  
DOCUMENT NUMBER: 133:30571  
TITLE: Preparation of aralkylamines active at receptor-operated calcium channels as neuroprotectants  
INVENTOR(S): Mueller, Alan L.; Balandrin, Manuel F.; Vanwagenen, Bradford C.; Delmar, Eric G.; Moe, Scott T.; Artman, Linda D.; Barmore, Robert M.  
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA  
SOURCE: U.S., 133 pp., Cont.-in-part of WO 9511663.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 6071970 A 20000606 US 1995-485038 19950607  
CA 2182680 AA 19950817 CA 1994-2182680 19941026  
WO 9521612 A2 19950817 WO 1994-US12293 19941026  
WO 9521612 A3 19950921  
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,  
GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG,  
MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA,  
US, US  
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN,  
TD, TG  
CN 1148337 A 19970423 CN 1994-195074 19941026  
ES 2156162 T3 20010616 ES 1994-932057 19941026  
EP 1123922 A2 20010816 EP 2000-121960 19941026  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE  
CA 2223978 AA 19961219 CA 1996-2223978 19960607  
WO 9640097 A1 19961219 WO 1996-US10201 19960607  
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,  
ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT,  
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI  
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
AU 9661125 A1 19961230 AU 1996-61125 19960607  
AU 716122 B2 20000217  
EP 831799 A1 19980401 EP 1996-918477 19960607  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI  
CN 1192679 A 19980909 CN 1996-196042 19960607  
JP 11506469 T2 19990608 JP 1996-502238 19960607  
BR 9609019 A 19990706 BR 1996-9019 19960607  
US 6017965 A 20000125 US 1996-763480 19961211  
US 6211245 B1 20010403 US 1998-186341 19981104  
US 6051610 A 20000418 US 1999-252433 19990218  
US 2002004522 A1 20020110 US 2001-825373 20010402  
PRIORITY APPLN. INFO.:  
US 1993-14813 B2 19930208  
US 1994-194210 B2 19940208  
US 1994-288668 B2 19940809  
WO 1994-US12293 A2 19941026  
US 1994-288688 A2 19940811  
EP 1994-932057 A3 19941026  
US 1995-485038 A 19950607  
US 1996-663013 A2 19960607  
WO 1996-US10201 W 19960607  
US 1996-763480 A2 19961211  
US 1997-869154 B2 19970604  
US 1997-873011 A1 19970611  
US 1998-186341 A1 19981104  
OTHER SOURCE(S): MARPAT 133:30571  
AB Title compds., e.g., RCHR4CR1R5CR2R6R7 [R = (un)substituted Ph; R1,R5 = H,  
OH, (hydroxy)alkyl, alkoxy, acyloxy; R2,R6 = H or hydroxyalkyl; R1R2 =  
(CH2)n or (CH2)nNR3; R3 = H, alkyl, CH2CH2OH; R4 = (cyclo)alkyl, or  
(un)substituted Ph; R7 = N(R3)2; R7 = H when R1R2 = (CH2)nNR3; n = 1-6]  
were prepd. Thus, (4-FC6H4)2CO was condensed with (EtO)2P(O)CH2CN and the  
product converted in 2 redn. steps to (4-FC6H4)2CHCH2CH2NH2. Data for  
biol. activity of title compds. were given.  
IT 17480-69-2, (S)-N-Benzyl-.alpha.-methylbenzylamine  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of aralkylamines active at **receptor**-operated  
**calcium** channels as neuroprotectants)  
RN 17480-69-2 CAPLUS  
CN Benzenemethanamine, .alpha.-methyl-N-(phenylmethyl)-, (.alpha.S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT.

L53 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3  
ACCESSION NUMBER: 2000:140602 CAPLUS  
DOCUMENT NUMBER: 132:203164  
TITLE: Calcium receptor-active molecules  
INVENTOR(S): Nemeth, Edward F.; Van Wanegen, Bradford C.;  
Balandrin, Manuel F.; Delmar, Eric M.; Moe, Scott T.  
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA  
SOURCE: U.S., 194 pp., Cont.-in-part of U.S. Ser. No. 353,784.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 9  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6031003	A	20000229	US 1995-484719	19950607
JP 09281209	A2	19971031	JP 1996-232165	19920821
JP 09328420	A2	19971222	JP 1996-232130	19920821
JP 11221095	A2	19990817	JP 1998-313631	19920821
JP 3256502	B2	20020212		
JP 2001220356	A2	20010814	JP 2000-394979	19920821
CN 1071333	A	19930428	CN 1992-111580	19920822
CN 1067550	B	20010627		
IL 102917	A1	20001206	IL 1992-102917	19920823
ZA 9206360	A	19930330	ZA 1992-6360	19920824
CA 2173747	AA	19950427	CA 1994-2173747	19941021
WO 9511221	A1	19950427	WO 1994-US12117	19941021
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9480872	A1	19950508	AU 1994-80872	19941021
AU 702629	B2	19990225		
EP 724561	A1	19960807	EP 1994-931982	19941021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1139917	A	19970108	CN 1994-194577	19941021
JP 09504032	T2	19970422	JP 1994-512244	19941021
US 6011068	A	20000104	US 1994-353784	19941208
AU 9671977	A1	19970220	AU 1996-71977	19961125
AU 711247	B2	19991007		
AU 9931226	A1	19990722	AU 1999-31226	19990524
PRIORITY APPLN. INFO.:				
			US 1991-749451	B2 19910823
			US 1992-834044	B2 19920211
			US 1992-934161	B2 19920821
			US 1993-17127	B2 19930212
			US 1993-9389	B2 19930223
			US 1993-141248	B2 19931022

US 1994-292827 B2 19940819  
WO 1994-US12117 A2 19941021  
US 1994-353784 A2 19941208  
JP 1992-504650 A3 19920821  
JP 1996-232165 A3 19920821  
JP 1998-313631 A3 19920821  
AU 1994-80872 A3 19941021

OTHER SOURCE(S): MARPAT 132:203164

AB The present invention relates to the different roles inorg. ion receptors have in cellular and body processes. The present invention features: (1) mols. which can modulate one or more inorg. ion receptor activities, preferably the mol. can mimic or block an effect of an extracellular ion on a cell having an inorg. ion receptor, more preferably the extracellular ion is Ca<sup>2+</sup> and the effect is on a cell having a calcium receptor; (2) inorg. ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorg. ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorg. ion receptor proteins, preferably calcium receptor protein; and (5) uses of such mols., proteins, nucleic acids and antibodies. For example, NPS R-568 ((R)-(+)-N-[3-(2-chlorophenyl)propyl]-.alpha.-methyl-3-methoxybenzylamine) was synthesized and its effectiveness was evaluated in a placebo-controlled, single-dose, dose-escalation format in a healthy, post-menopausal women. NPS R-568 caused a transient dose-dependent decrease in plasma PTH concn., and , at higher doses, a decrease in serum ionized serum concn. in the human subject. There was no apparent change in serum calcitonin at the doses studied. Higher doses are expected to affect calcitonin levels as obsd. in rats.

IT 148740-52-7, NPS S-467 159149-75-4, NPS S-568

199614-43-2 199614-44-3


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(calcium receptor-active mols. for treatment of osteoporosis and related disorders)

RN 148740-52-7 CAPLUS

CN Benzenepropanamine, N-[(1S)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159149-75-4 CAPLUS


CN Benzenepropanamine, 2-chloro-N-[(1S)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199614-43-2 CAPLUS  
 CN Benzenepropanamine, N-[(1S)-1-(2,5-dimethoxyphenyl)ethyl]- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 199614-44-3 CAPLUS  
 CN Benzenepropanamine, N-[(1R)-1-(2,5-dimethoxyphenyl)ethyl]- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



IT 66469-40-7P 148717-47-9P, NPS 467 148717-48-0P  
 148717-49-1P, NPS 568 148717-54-8P, NPS R-568  
 148717-56-0P, NPS R-467 159149-76-5P  
 159149-96-9P 159149-97-0P 159149-98-1P  
 159149-99-2P 159150-00-2P 159150-03-5P  
 159150-04-6P 159150-05-7P 159150-06-8P  
 159150-17-1P 159150-18-2P 159150-19-3P  
 159150-20-6P 159150-28-4P 159247-74-2P  
 165304-87-0P 179381-56-7P 179381-60-3P  
 179381-62-5P 179381-67-0P 179381-69-2P  
 179381-70-5P 179381-74-9P 179381-75-0P  
 179603-34-0P 179603-36-2P 179603-37-3P  
 179603-38-4P 179603-40-8P 179603-41-9P  
 179603-42-0P 199614-53-4P 199614-61-4P  
 199614-63-6P 199614-68-1P 199614-73-8P

199614-84-1P 199614-85-2P 199614-86-3P  
199614-87-4P 199614-89-6P 199614-90-9P  
199614-91-0P 199614-93-2P 199614-94-3P  
199614-95-4P 199614-97-6P 199614-98-7P  
199614-99-8P 199615-00-4P 199615-01-5P  
199615-02-6P 199615-03-7P 199615-05-9P  
199615-06-0P 199615-07-1P 199615-08-2P  
199615-09-3P 199615-11-7P 199615-13-9P  
199615-14-0P 199615-15-1P 199615-16-2P  
199615-17-3P 199615-18-4P 199615-22-0P  
199615-23-1P 199615-25-3P 199615-26-4P  
199615-27-5P 199615-28-6P 199615-29-7P  
219686-00-7P 219686-01-8P 226256-47-9P  
252055-76-8P 252055-78-0P 252055-80-4P  
252055-81-5P 252055-83-7P 252055-88-2P  
252056-03-4P 252056-10-3P 253337-19-8P  
253337-22-3P 253337-23-4P 253337-24-5P  
253337-26-7P 253337-27-8P 253337-28-9P  
253337-29-0P 253337-30-3P 253337-32-5P  
253337-33-6P 253337-34-7P 253337-35-8P  
253337-36-9P 253337-39-2P 253337-41-6P  
253337-42-7P 253337-43-8P 253337-44-9P  
253337-45-0P 253337-46-1P 253337-47-2P  
253337-49-4P 253337-50-7P 253337-51-8P  
253337-52-9P 253337-53-0P 253337-54-1P  
253337-55-2P 253337-56-3P 253337-57-4P  
253337-58-5P 253337-59-6P 253337-60-9P  
253337-61-0P 253337-62-1P 253337-63-2P  
253337-64-3P 253337-65-4P 253337-66-5P  
259855-78-2P 259855-79-3P 259855-80-6P  
259855-81-7P 259855-83-9P 259855-84-0P  
259855-85-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of **calcium receptor**-active mols. for treatment of osteoporosis and related disorders)

RN 66469-40-7 CAPLUS


CN 1-Naphthalenemethanamine, .alpha.-methyl-N-(phenylmethyl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 148717-47-9 CAPLUS


CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 148717-48-0 CAPLUS  
 CN Benzenepropanamine, N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 148717-49-1 CAPLUS  
 CN Benzenepropanamine, 2-chloro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 148717-54-8 CAPLUS  
 CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 148717-56-0 CAPLUS  
 CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 159149-76-5 CAPLUS

CN Benzenepropanamine, 3-fluoro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159149-96-9 CAPLUS


CN 2-Naphthalenemethanamine, N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159149-97-0 CAPLUS

CN Benzenepropanamine, 2-fluoro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159149-98-1 CAPLUS


CN Benzenepropanamine, 3-fluoro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159149-99-2 CAPLUS  
CN Benzenepropanamine, 4-fluoro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159150-00-2 CAPLUS  
CN Benzenepropanamine, 4-chloro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159150-03-5 CAPLUS  
CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 159150-04-6 CAPLUS  
CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 159150-05-7 CAPLUS  
CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 159150-06-8 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[1-(3-methoxyphenyl)ethyl]-.gamma.-methyl-  
(9CI) (CA INDEX NAME)

RN 159150-17-1 CAPLUS


CN 1-Naphthalenemethanamine, N-[1-(3-methoxyphenyl)ethyl]-.alpha.-methyl-  
(9CI) (CA INDEX NAME)

RN 159150-18-2 CAPLUS

CN 2-Naphthalenemethanamine, N-[1-(3-methoxyphenyl)ethyl]-.alpha.-methyl-  
(9CI) (CA INDEX NAME)


RN 159150-19-3 CAPLUS

CN 1-Naphthalenemethanamine, N-[3-(2-chlorophenyl)propyl]-.alpha.-methyl-  
(9CI) (CA INDEX NAME)




RN 159150-20-6 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[1-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159150-28-4 CAPLUS

CN Ethanone, 1-[3-[1-[(3-phenylpropyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 159247-74-2 CAPLUS


CN Benzenepropanamine, 3-chloro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 165304-87-0 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[1-(1-naphthalenyl)ethyl]-, (R\*,S\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 179381-56-7 CAPLUS

CN Benzenepropanamine, 2-methoxy-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 179381-60-3 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[[4-(1-methylethyl)phenyl]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179381-62-5 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179381-67-0 CAPLUS

CN 1-Naphthalenemethanamine, N-[(3-chloro-4-methoxyphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179381-69-2 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179381-70-5 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(3-chloro-4-methoxyphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179381-74-9 CAPLUS


CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179381-75-0 CAPLUS  
CN 1-Naphthalenemethanamine, N-[3-(2-chlorophenyl)propyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179603-34-0 CAPLUS  
CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-.alpha.-  
methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179603-36-2 CAPLUS  
CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-.alpha.-methyl-,  
(.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179603-37-3 CAPLUS

CN Benzenepropanamine, 3-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179603-38-4 CAPLUS

CN Benzenepropanamine, 4-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179603-40-8 CAPLUS

CN Benzenemethanamine, 3-methoxy-N-[(1S)-1-(4-methoxyphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179603-41-9 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-ethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 179603-42-0 CAPLUS


CN Benzenepropanamine, N-[(1R)-1-(3-ethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199614-53-4 CAPLUS


CN 1-Naphthalenemethanamine, N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 199614-61-4 CAPLUS


CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199614-63-6 CAPLUS  
 CN 2-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-phenylethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 199614-68-1 CAPLUS  
 CN Benzenepropanamine, 4-fluoro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 199614-73-8 CAPLUS  
 CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-.alpha.-  
 methyl-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199614-84-1 CAPLUS  
 CN Benzenepropanamine, N-[1-[3-(methylthio)phenyl]ethyl]- (9CI) (CA INDEX  
 NAME)




RN 199614-85-2 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[1-[3-(methylthio)phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 199614-86-3 CAPLUS

CN Benzenepropanamine, N-[1-(3-bromophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 199614-87-4 CAPLUS


CN Benzenepropanamine, 3,4,5-trimethoxy-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 199614-89-6 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199614-90-9 CAPLUS


CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[1-(2-naphthalenyl)ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199614-91-0 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-(2-naphthalenylmethyl)-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199614-93-2 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-(2-naphthalenyl)ethyl]-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199614-94-3 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1S)-1-(2-naphthalenyl)ethyl]-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199614-95-4 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1S)-2-methyl-1-(2-naphthalenyl)propyl]-,  
(.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199614-97-6 CAPLUS

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-[[4-(1-methylethyl)phenyl]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199614-98-7 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN' 199614-99-8 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-00-4 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(4-propoxyphenyl)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-01-5 CAPLUS

CN 1-Naphthalenemethanamine, N-[(3,4-dichlorophenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-02-6 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[[4-(trifluoromethyl)phenyl]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-03-7 CAPLUS

CN 1-Naphthalenemethanamine, N-[(4-methoxyphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-05-9 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-[4-(1-methylethyl)phenyl]ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-06-0 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(3-chlorophenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-07-1 CAPLUS


CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxyphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199615-08-2 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(1S)-1-(4-methoxyphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199615-09-3 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-11-7 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(4-methoxy-3-methylphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 199615-13-9 CAPLUS

CN 1-Naphthalenemethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-14-0 CAPLUS

CN 1-Naphthalenemethanamine, N-[(3,4-dimethylphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-15-1 CAPLUS

CN 1-Naphthalenemethanamine, N-[(4-ethoxyphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-16-2 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[[4-(methythio)phenyl]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-17-3 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(3-fluoro-4-methoxyphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-18-4 CAPLUS


CN Phenol, 2-methyl-4-[(1R)-1-[(1R)-1-(1-naphthalenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199615-22-0 CAPLUS

CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]-.alpha.-methyl- (9CI)  
(CA INDEX NAME)



RN 199615-23-1 CAPLUS


CN Benzenepropanamine, .alpha.-ethyl-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA  
INDEX NAME)



RN 199615-25-3 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1S)-1-methyl-3-phenylpropyl]-  
, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-26-4 CAPLUS


CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-2-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199615-27-5 CAPLUS  
CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-3-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199615-28-6 CAPLUS  
CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199615-29-7 CAPLUS  
CN Benzenepropanamine, 2-fluoro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



RN 219686-00-7 CAPLUS  
CN Benzenepropanamine, 3-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-.gamma.-  
methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219686-01-8 CAPLUS

CN Benzenepropanamine, 4-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-.gamma.-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 226256-47-9 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-76-8 CAPLUS

CN 1-Naphthalenemethanamine, N-[(3-chlorophenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-78-0 CAPLUS


CN 1-Naphthalenemethanamine, N-[(4-ethylphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252055-80-4 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(4-chlorophenyl)methyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252055-81-5 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(4-methylphenyl)methyl]-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252055-83-7 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(4-fluorophenyl)methyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252055-88-2 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1S)-1-[4-(1-methylethyl)phenyl]ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252056-03-4 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-chlorophenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252056-10-3 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(1S)-1-(4-chlorophenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-19-8 CAPLUS  
 CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-22-3 CAPLUS  
 CN Phenol, 4-[(1R)-1-[[3-(2-chlorophenyl)propyl]amino]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253337-23-4 CAPLUS  
 CN Benzenepropanamine, N-[(1R)-1-[3-(trifluoromethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-24-5 CAPLUS



CN Benzenepropanamine, 2-chloro-N-[(1R)-1-[3-(trifluoromethoxy)phenyl]ethyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253337-26-7 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-(3-phenylpropyl)-, (.alpha.R)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253337-27-8 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-(6-methyl-2-naphthalenyl)ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253337-28-9 CAPLUS

CN 2-Naphthalenemethanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-.alpha.-(1-methylethyl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-29-0 CAPLUS

CN 2-Naphthalenemethanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-.alpha.-(1-

methylethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253337-30-3 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxy-2-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253337-32-5 CAPLUS

CN 1-Naphthalenemethanamine, N-[(3-methoxyphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253337-33-6 CAPLUS


CN 1-Naphthalenemethanamine, N-[(2-methoxyphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-34-7 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(1S)-1-(3-methoxyphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-35-8 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(6-methoxy-2-naphthalenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-36-9 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(3,4,5-trimethoxyphenyl)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-39-2 CAPLUS  
 CN 1-Naphthalenemethanamine, N-[3-(2-methoxyphenyl)propyl]-.alpha.-methyl-,  
 (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-41-6 CAPLUS  
 CN Benzenemethanamine, 3-methoxy-N-[(1R)-1-(3-methoxyphenyl)ethyl]-.alpha.-  
 methyl-, (.alpha.S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 253337-42-7 CAPLUS  
 CN 1-Naphthalenemethanamine, N-[(3,4-dimethoxyphenyl)methyl]-.alpha.-methyl-,  
 (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-43-8 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(2,4-dimethoxyphenyl)methyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-44-9 CAPLUS  
CN 1-Naphthalenemethanamine, N-[1-(3,4-dichlorophenyl)ethyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-45-0 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(4-methoxy-2,3-dimethylphenyl)methyl]-.alpha.-  
methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-46-1 CAPLUS  
 CN 1-Naphthalenemethanamine, N-[(1R)-1-(3,4-dimethylphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-47-2 CAPLUS  
 CN Phenol, 3-[(1R)-1-[[3-(2-chlorophenyl)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-49-4 CAPLUS  
 CN 1-Naphthalenemethanamine, N-[(4-methoxy-3-methylphenyl)methyl]-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 253337-50-7 CAPLUS

CN 1-Naphthalenemethanamine, 4-fluoro-N-[(4-methoxy-3-methylphenyl)methyl]-  
.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 253337-51-8 CAPLUS

CN 1-Naphthalenemethanamine, 2-methoxy-N-[(4-methoxy-3-methylphenyl)methyl]-  
.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 253337-52-9 CAPLUS  
CN 1-Naphthalenemethanamine, 4-methoxy-N-[(4-methoxy-3-methylphenyl)methyl]-  
.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 253337-53-0 CAPLUS  
CN 1-Naphthalenemethanamine, 5-methoxy-N-[(4-methoxy-3-methylphenyl)methyl]-  
.alpha.-methyl- (9CI) (CA INDEX NAME)






RN 253337-54-1 CAPLUS

CN 1-Naphthalenemethanamine, 6-methoxy-N-[(4-methoxy-3-methylphenyl)methyl]-  
.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 253337-55-2 CAPLUS

CN 1-Naphthalenemethanamine, 7-methoxy-N-[(4-methoxy-3-methylphenyl)methyl]-  
.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 253337-56-3 CAPLUS

CN Benzenemethanamine, 4-fluoro-3-methoxy-N-[(4-methoxy-3-methylphenyl)methyl]-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 253337-57-4 CAPLUS

CN Benzenemethanamine, 3-methoxy-N-[(4-methoxy-3-methylphenyl)methyl]-.alpha.,4-dimethyl- (9CI) (CA INDEX NAME)



RN 253337-58-5 CAPLUS


CN Benzenemethanamine, N-[(4-methoxy-3-methylphenyl)methyl]-.alpha.,3,4-trimethyl- (9CI) (CA INDEX NAME)



RN 253337-59-6 CAPLUS


CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[3-(2-methylphenyl)propyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-60-9 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[3-(3-methylphenyl)propyl]-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-61-0 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[3-(4-methylphenyl)propyl]-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253337-62-1 CAPLUS  
CN 1-Naphthalenemethanamine, N-[3-(2,4-dimethylphenyl)propyl]-.alpha.-methyl-  
, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253337-63-2 CAPLUS  
 CN Benzenepropanamine, 2-chloro-N-[1-(4-fluoro-3-methoxyphenyl)ethyl]- (9CI)  
 (CA INDEX NAME)




RN 253337-64-3 CAPLUS  
 CN Benzenepropanamine, 2-chloro-N-[1-(2,3-difluorophenyl)ethyl]- (9CI) (CA  
 INDEX NAME)




RN 253337-65-4 CAPLUS  
 CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-2-(trifluoromethoxy)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 253337-66-5 CAPLUS  
 CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-4-(trifluoromethoxy)-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259855-78-2 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-2,3-dimethyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 259855-79-3 CAPLUS

CN 1-Naphthalenemethanamine, N-[(4-methoxy-2-naphthalenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259855-80-6 CAPLUS

CN 1-Naphthalenemethanamine, N-[(3-methoxy-2-naphthalenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259855-81-7 CAPLUS

CN Benzenemethanamine, 3-methoxy-N-[(1R)-1-(3-methoxyphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259855-83-9 CAPLUS

CN Phenol, 3-[(1R)-1-[[3-(2-iodophenyl)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259855-84-0 CAPLUS

CN Benzenepropanamine, 3-methoxy-N-[(1R)-1-(3-methoxyphenyl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259855-85-1 CAPLUS

CN Ethanone, 1-[3-[(1R)-1-[(3-phenylpropyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 199615-10-6


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of **calcium receptor**-active mols. for treatment of osteoporosis and related disorders)

RN 199615-10-6 CAPLUS

CN 1-Naphthalenemethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 179381-55-6P 179381-59-0P 179381-63-6P

179381-65-8P 179381-66-9P 252055-41-7P


259855-86-2P 259855-87-3P 259855-88-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of **calcium receptor**-active mols. for  
treatment of osteoporosis and related disorders)

RN 179381-55-6 CAPLUS

CN Benzenepropanamine, 2-methoxy-N-[(1R)-1-(3-methoxyphenyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 179381-59-0 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[[4-(1-methylethyl)phenyl]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 179381-63-6 CAPLUS  
 CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 179381-65-8 CAPLUS  
 CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxyphenyl)ethyl]-.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 179381-66-9 CAPLUS  
 CN 1-Naphthalenemethanamine, N-[(3-chloro-4-methoxyphenyl)methyl]-.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.




● HCl

RN 252055-41-7 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-(2-naphthalenyl)ethyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 259855-86-2 CAPLUS

CN Benzenepropanamine, N-[1-[3-(methylthio)phenyl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 259855-87-3 CAPLUS

CN 1-Naphthalenemethanamine, N-[3-(2-chlorophenyl)propyl]-.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 259855-88-4 CAPLUS

CN 1-Naphthalenemethanamine, N-[(4-methoxy-3-methylphenyl)methyl]-.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L53 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 4

ACCESSION NUMBER: 1999:794339 CAPLUS

DOCUMENT NUMBER: 132:35523

TITLE: Preparation of new bis(arylalkyl)amines as calcium receptor-active molecules

INVENTOR(S): Nemeth, Edward F.; Van Wagenen, Bradford C.; Balandrin, Manuel F.; Delmar, Eric G.; Moe, Scott T.

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA

SOURCE: U.S., 112 pp., Cont.-in-part of U.S. Ser. No. 353,784. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Searched by Barb O'Bryen, STIC 308-4291

US 6001884	A	19991214	US 1995-469204	19950606
JP 09281209	A2	19971031	JP 1996-232165	19920821
JP 09328420	A2	19971222	JP 1996-232130	19920821
JP 11221095	A2	19990817	JP 1998-313631	19920821
JP 3256502	B2	20020212		
JP 2001220356	A2	20010814	JP 2000-394979	19920821
CN 1071333	A	19930428	CN 1992-111580	19920822
CN 1067550	B	20010627		
IL 102917	A1	20001206	IL 1992-102917	19920823
ZA 9206360	A	19930330	ZA 1992-6360	19920824
CA 2173747	AA	19950427	CA 1994-2173747	19941021
WO 9511221	A1	19950427	WO 1994-US12117	19941021
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9480872	A1	19950508	AU 1994-80872	19941021
AU 702629	B2	19990225		
EP 724561	A1	19960807	EP 1994-931982	19941021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1139917	A	19970108	CN 1994-194577	19941021
JP 09504032	T2	19970422	JP 1994-512244	19941021
US 6011068	A	20000104	US 1994-353784	19941208
AU 9671977	A1	19970220	AU 1996-71977	19961125
AU 711247	B2	19991007		
AU 9931226	A1	19990722	AU 1999-31226	19990524
PRIORITY APPLN. INFO.:				
			US 1991-749451	B2 19910823
			US 1992-834044	B2 19920211
			US 1992-934161	B2 19920821
			US 1993-17127	B2 19930212
			US 1993-9389	B2 19930223
			US 1993-141248	B2 19931022
			US 1994-292827	B2 19940819
			WO 1994-US12117	A2 19941021
			US 1994-353784	A2 19941208
			JP 1992-504650	A3 19920821
			JP 1996-232165	A3 19920821
			JP 1998-313631	A3 19920821
			AU 1994-80872	A3 19941021
OTHER SOURCE(S): MARPAT 132:35523				
GI				



AB The invention features mols. such as I, and other similar mols., which can modulate one or more activities of an inorg. ion receptor [wherein X, Y = Me, OMe, OEt, methylenedioxy, halo, CF<sub>3</sub>, OH, CH<sub>2</sub>OH, alkyl, OAc,

(un)substituted benzo fusion, etc.; R = H, alkyl, allyl, cycloalkyl, indanyl, indenyl, piperidyl, etc.; m, n = 0-5; with provisos]. In particular, the mol. can mimic or block the effect of extracellular Ca<sup>2+</sup> on a calcium receptor. The preferred use of such mols. is to treat diseases or disorders by altering inorg. ion receptor activity, preferably calcium receptor activity. Uses include the treatment of hyperparathyroidism, Paget's disease, hypertension, osteoporosis, CNS injuries or disorders, and many others. For instance, 3'-aminoacetophenone was diazotized with NaNO<sub>2</sub> and HCl and then treated with aq. NaSMc to give 74% 3'-(methylthio)acetophenone, which was condensed with 3-phenylpropylamine and reduced with NaBH<sub>3</sub>CN to give title compd. II. The latter is one of several preferred compds. which showed high Ca<sup>2+</sup> ion receptor modulation during screening, e.g., with an EC<sub>50</sub> value of < 5 .mu.M.


IT 252056-35-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(in prepn. of new bis(arylalkyl)amines as **calcium receptor**-active mols.)

RN 252056-35-2 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1S)-1-(4-methoxy-3-methylphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219686-08-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate in prepn. of **calcium receptor**-active mols.)

RN 219686-08-5 CAPLUS

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-[3-(2-methylphenyl)-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



IT 66469-40-7P 159150-17-1P 179381-53-4P  
179381-56-7P 179381-59-0P 179381-60-3P  
179381-62-5P 179381-64-7P 179381-65-8P


179381-66-9P 179381-67-0P 179381-68-1P  
179381-69-2P 199614-61-4P 199614-84-1P  
199614-93-2P 199615-04-8P 199615-05-9P  
199615-07-1P 199615-10-6P 199615-12-8P  
252055-41-7P 252055-68-8P 252055-69-9P  
252055-70-2P 252055-71-3P 252055-74-6P  
252055-76-8P 252055-78-0P 252055-80-4P  
252055-81-5P 252055-83-7P 252055-88-2P  
252055-98-4P 252056-03-4P 252056-10-3P  
252056-24-9P 252056-29-4P 252056-30-7P  
252056-32-9P 252056-33-0P 252056-34-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of new bis(arylalkyl)amines as **calcium receptor**-active mols.)

RN 66469-40-7 CAPLUS


CN 1-Naphthalenemethanamine, .alpha.-methyl-N-(phenylmethyl)-, (.alpha.R)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 159150-17-1 CAPLUS

CN 1-Naphthalenemethanamine, N-[1-(3-methoxyphenyl)ethyl]-.alpha.-methyl-  
(9CI) (CA INDEX NAME)




RN 179381-53-4 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-(3-phenylpropyl)- (9CI) (CA  
INDEX NAME)




RN 179381-56-7 CAPLUS  
 CN Benzenepropanamine, 2-methoxy-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179381-59-0 CAPLUS  
 CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[[4-(1-methylethyl)phenyl]methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 179381-60-3 CAPLUS  
 CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[[4-(1-methylethyl)phenyl]methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179381-62-5 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179381-64-7 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179381-65-8 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxyphenyl)ethyl]-.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 179381-66-9 CAPLUS

CN 1-Naphthalenemethanamine, N-[(3-chloro-4-methoxyphenyl)methyl]-.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 179381-67-0 CAPLUS

CN 1-Naphthalenemethanamine, N-[(3-chloro-4-methoxyphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 179381-68-1 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)ethyl]-  
.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 179381-69-2 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)ethyl]-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 199614-61-4 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-phenylethyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 199614-84-1 CAPLUS  
CN Benzenepropanamine, N-[1-[3-(methylthio)phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 199614-93-2 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-(2-naphthalenyl)ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199615-04-8 CAPLUS  
CN 1,4-Benzodioxin-6-methanamine, 2,3-dihydro-N-[(1R)-1-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199615-05-9 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-[4-(1-methylethyl)phenyl]ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-07-1 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxyphenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-10-6 CAPLUS

CN 1-Naphthalenemethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199615-12-8 CAPLUS

CN 1,3-Benzodioxole-5-methanamine, N-[(1R)-1-(1-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-41-7 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-(2-naphthalenyl)ethyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 252055-68-8 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-2-methyl-1-(2-naphthalenyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-69-9 CAPLUS

CN 1-Naphthalenemethanamine, N-[(1R)-1-(1-methoxy-2-naphthalenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-70-2 CAPLUS


CN 1-Naphthalenemethanamine, N-[(1S)-1-(1-methoxy-2-naphthalenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252055-71-3 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-(1-naphthalenylmethyl)-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252055-74-6 CAPLUS  
CN 2-Naphthalenemethanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 252055-76-8 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(3-chlorophenyl)methyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252055-78-0 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(4-ethylphenyl)methyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-80-4 CAPLUS

CN 1-Naphthalenemethanamine, N-[(4-chlorophenyl)methyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-81-5 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(4-methylphenyl)methyl]-,  
(.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-83-7 CAPLUS

CN 1-Naphthalenemethanamine, N-[(4-fluorophenyl)methyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-88-2 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1S)-1-[4-(1-methylethyl)phenyl]ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252055-98-4 CAPLUS

CN 1-Naphthalenemethanamine, N-[1-(3-chlorophenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252056-03-4 CAPLUS


CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-chlorophenyl)ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252056-10-3 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(1S)-1-(4-chlorophenyl)ethyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252056-24-9 CAPLUS  
CN 1-Naphthalenemethanamine, N-[1-(4-methoxyphenyl)propyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252056-29-4 CAPLUS  
CN 1-Naphthalenemethanamine, 4-chloro-N-[(4-methoxy-3-methylphenyl)methyl]-  
.alpha.-methyl- (9CI) (CA INDEX NAME)





RN 252056-30-7 CAPLUS


CN 1-Naphthalenemethanamine, 8-chloro-N-[(4-methoxy-3-methylphenyl)methyl]-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 252056-32-9 CAPLUS


CN 1-Naphthalenemethanamine, N-[1-[4-(1,1-dimethylethyl)phenyl]ethyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252056-33-0 CAPLUS  
CN Benzenemethanamine, N-[1-[4-(1,1-dimethylethyl)phenyl]ethyl]-3-methoxy-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252056-34-1 CAPLUS  
CN 1-Naphthalenemethanamine, N-[(4-methoxy-2,5-dimethylphenyl)methyl]-.alpha.-  
methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L53 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:122163 CAPLUS

DOCUMENT NUMBER: 136:398803

TITLE: Evidence for calcium-sensing receptor mediated  
stanniocalcin secretion in fish

AUTHOR(S): Radman, Dennis P.; McCudden, Christopher; James,  
Kathi; Nemeth, Edward M.; Wagner, Graham F.

CORPORATE SOURCE: Faculty of Medicine and Dentistry, Department of  
Physiology, The University of Western Ontario, London,  
ON, N6A 5C1, Can.

SOURCE: Molecular and Cellular Endocrinology (2002), 186(1),  
111-119

CODEN: MCEND6; ISSN: 0303-7207

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB As in the case of parathyroid hormone (PTH) and calcitonin (CT), the  
secretion of stanniocalcin (STC) in fish is tightly regulated by the  
levels of extracellular Ca<sup>2+</sup>. Fish STC functions as an anti-hypercalcemic  
hormone such that a rise in extracellular Ca<sup>2+</sup> above the physiol.  
set-point of .apprx.1.2 mM provokes an immediate secretory response.  
Whether or not Ca<sup>2+</sup>-regulated STC secretion in fishes is mediated by  
similar type of receptor has never been addressed. Here, we have found  
that Ca<sup>2+</sup>-stimulated STC secretion in salmon is mimicked by


calcium-sensing receptor (CaR) mimetics, pharmacol. agents that increase the sensitivity of the CaR to calcium. NPS 467, a small org. mol. that acts as a pos. allosteric modulator of the CaR and alters calciotropic hormone secretion in mammals, was examd. for effects on serum levels of STC in trout. The i.p. administration of NPS R-467 had time- and dose-dependent stimulatory effects on STC secretion that were indistinguishable from those of Ca<sup>2+</sup> loading. The effects of NPS 467 were stereospecific and had no effects on serum CT. NPS 467 induced STC release was also manifested by a downstream physiol. response; the inhibition of gill calcium transport. A cDNA clone was amplified from a fish corpuscle of Stannius cDNA library with high homol. to the human CaR. RT-PCR revealed that this transcript was also present in gill, kidney, pancreas, brain, muscle, and spleen. These findings suggest that Ca<sup>2+</sup>-stimulated STC secretion in fishes is mediated by a calcium ion-sensing receptor similar to that in mammals.

IT 148717-47-9, NPS 467

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(calcium-sensing receptor mediated stanniocalcin secretion in fish)

RN 148717-47-9 CAPLUS

CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L53 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:486388 CAPLUS

DOCUMENT NUMBER: 131:237804

TITLE: Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca<sup>2+</sup> receptor in rats

AUTHOR(S): Fox, John; Lowe, Stacey H.; Conklin, Rebecca L.; Petty, Barbara A.; Nemeth, Edward F.

CORPORATE SOURCE: NPS Pharmaceuticals, Inc., Salt Lake City, UT, USA  
SOURCE: Journal of Pharmacology and Experimental Therapeutics (1999), 290(2), 480-486  
CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB N-(3-[2-Chlorophenyl]propyl)-(R)-.alpha.-methyl-3-methoxybenzylamine (NPS R-568) is an orally active compd. that activates Ca<sup>2+</sup> receptors on parathyroid cells and rapidly suppresses plasma levels of parathyroid hormone (PTH) and Ca<sup>2+</sup> (ED<sub>50</sub>, 1 and 10 mg/kg, resp.). We now show that increased calcitonin secretion contributes to NPS R-568-induced hypocalcemia. In parathyroidectomized thyroid-intact rats in which normocalcemia was restored by PTH infusion, NPS R-568 rapidly reduced plasma Ca<sup>2+</sup> levels, indicating that decreased PTH secretion was not solely responsible for the hypocalcemia seen in normal animals. NPS R-568 decreased plasma Ca<sup>2+</sup> levels in thyroidectomized parathyroid-intact rats, but the rate of onset of hypocalcemia was slower than in controls. In contrast, NPS R-568 had no effect on plasma Ca<sup>2+</sup> levels in PTH-infused, thyroparathyroidectomized rats, providing evidence that increased

calcitonin secretion caused the hypocalcemia in PTH-infused parathyroidectomized rats. NPS R-568 rapidly increased plasma calcitonin levels to a peak at 10 to 20 min after oral dosing (ED50 40 mg/kg). NPS R-568 did not affect the rate of disappearance of  $^{45}\text{Ca}$  from blood, indicating that hypocalcemia resulted from decreased influx of  $\text{Ca}^{2+}$  into the circulation and not from increased efflux. This suggests that NPS R-568-induced hypocalcemia resulted solely from reduced efflux of  $\text{Ca}^{2+}$  from bone after increased calcitonin and reduced PTH secretion. Thus, NPS R-568 causes hypocalcemia by activating  $\text{Ca}^{2+}$  receptors on C cells and parathyroid cells; however, NPS R-568 is about 40 times more potent in reducing PTH levels than in increasing calcitonin levels.

IT 148717-54-8, NPS R-568


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(calcimimetic NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland **calcium receptor** in rats)

RN 148717-54-8 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L53 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:486387 CAPLUS

DOCUMENT NUMBER: 131:223309

TITLE: NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium

AUTHOR(S): Fox, John; Lowe, Stacey H.; Petty, Barbara A.; Nemeth, Edward F.

CORPORATE SOURCE: NPS Pharmaceuticals, Inc., Salt Lake City, UT, USA  
SOURCE: Journal of Pharmacology and Experimental Therapeutics (1999), 290(2), 473-479

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Calcimimetics like N-(3-[2-chlorophenyl]propyl)-(R)-.alpha.-methyl-3-methoxybenzylamine (NPS R-568) potentiate the effects of extracellular  $\text{Ca}^{2+}$  on parathyroid  $\text{Ca}^{2+}$  receptors and inhibit parathyroid hormone (PTH) secretion in vitro. When administered by gavage to normal rats in this study, NPS R-568 caused a rapid, dose-dependent (ED50, 1.1+-.0.7 mg/kg) decrease in PTH levels that was paralleled by a subsequent decrease in plasma  $\text{Ca}^{2+}$  (ED50, 10.4+-.3.7 mg/kg). At higher doses (.gtoreq.3.3 mg/kg), PTH was reduced to a min. level within 15 min, the duration of which was dose dependent. With doses of 10 to 100 mg/kg, the hypocalcemia was rapid in onset (<30 min) and, at 33 to 100 mg/kg, persisted for >24 h. Neither the magnitude nor the kinetics of the hypocalcemic response was affected by total nephrectomy, demonstrating that NPS R-568 does not induce hypocalcemia by acting on renal  $\text{Ca}^{2+}$  receptors to increase  $\text{Ca}^{2+}$

excretion. In contrast, parathyroidectomy (intact thyroid) abolished the hypocalcemic response to NPS R-568, regardless of whether the rats were hypocalcemic or rendered acutely normo- or hypercalcemic by calcium infusion before dosing. These data show that the parathyroid  $\text{Ca}^{2+}$  receptor can be selectively activated in vivo with a small org. compd. to decrease plasma levels of PTH and  $\text{Ca}^{2+}$  and thus define the mechanism of action of this compd. in vivo. Moreover, the data add pharmacol. support to the view that the  $\text{Ca}^{2+}$  receptor is the primary mol. entity regulating systemic  $\text{Ca}^{2+}$  homeostasis.

IT 148717-54-8, NPS R-568


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(type II calcimimetic compd. NPS R-568 acts on parathyroid cell **calcium receptor** of rats and reduces plasma levels of parathyroid hormone and **calcium**)

RN 148717-54-8 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L53 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:7958 CAPLUS

DOCUMENT NUMBER: 130:66268

TITLE: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

INVENTOR(S): Mueller, Alan L.; Moe, Scott T.

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 252 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856752	A1	19981217	WO 1998-US11608	19980611
W: JP				
PRIORITY APPLN. INFO.:			US 1997-873011	A 19970611
OTHER SOURCE(S):		MARPAT 130:66268		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The compds. [I, II, III; R1 and R3 are independently selected from

(un)substituted Ph, benzyl, phenoxy, H, alkyl, OH, etc.; R2 and R5 are independently selected from H, alkyl, hydroxyalkyl; R2-R5 together are imino; R1-R2 together are (CH2)n, (CH2)n-N(R6)-(CH2)n; n = 0-6, at least one n greater than 0; R6 is H, alkyl, 2-hydroxyethyl, and alkylphenyl; R4 is selected from (un)substituted thiofuryl, pyridyl, Ph, benzyl, phenoxy, phenylthio, H, alkyl, chcloalkyl; X, X1 is independently selected from (un)substituted Ph, benzyl, phenoxy, F, Cl, Br, Oh, etc.; m = 0-5; Y is N(R6)2, H when R1-R2 together are (CH2)n-N(R6)-(CH2)n], pharmaceutical compns., and pharmaceutical acceptable salts, complexes, and carriers are prep. as antagonists of NMDA receptor-mediated responses for treating a neurol. disease or disorder such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

IT 17480-69-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(compds. active at novel site on **receptor**-operated **calcium** channels useful for treatment of neurol. disorders and diseases)

RN 17480-69-2 CAPLUS

CN Benzenemethanamine, .alpha.-methyl-N-(phenylmethyl)-, (.alpha.S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L53 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:236107 CAPLUS

DOCUMENT NUMBER: 129:567

TITLE: Calcimimetics with potent and selective activity on the parathyroid calcium receptor

AUTHOR(S): Nemeth, Edward F.; Steffey, Michael E.; Hammerland, Lance G.; Hung, Benjamin C. P.; Van Wagenen, Bradford C.; Delmar, Eric G.; Balandrin, Manuel F.

CORPORATE SOURCE: NPS Pharmaceuticals, Inc., Salt Lake City, UT, 84108, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1998), 95(7), 4040-4045  
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Parathyroid hormone (PTH) secretion is regulated by a cell surface Ca2+ receptor that detects small changes in the level of plasma Ca2+. Because this G protein-coupled receptor conceivably provides a distinct mol. target for drugs useful in treating bone and mineral-related disorders, we sought to design small org. mols. that act on the Ca2+ receptor. We discovered that certain phenylalkylamine compds., typified by NPS R-568 and its deschloro deriv. NPS R-467, increased the concn. of cytoplasmic Ca2+ ([Ca2+]i) in bovine parathyroid cells and inhibited PTH secretion at

nanomolar concns. These effects were stereoselective and the R enantiomers were 10- to 100-fold more potent than the S enantiomers. NPS R-568 potentiated the effects of extracellular  $\text{Ca}^{2+}$  on  $[\text{Ca}^{2+}]_i$  and PTH secretion but was without effect in the absence of extracellular  $\text{Ca}^{2+}$ . Both compds. shifted the concn.-response curves for extracellular  $\text{Ca}^{2+}$  to the left. Presumably, these compds. act as pos. allosteric modulators to increase the sensitivity of the  $\text{Ca}^{2+}$  receptor to activation by extracellular  $\text{Ca}^{2+}$ . Both NPS R-467 and NPS R-568 increased  $[\text{Ca}^{2+}]_i$  in HEK 293 cells expressing the human parathyroid  $\text{Ca}^{2+}$  receptor but were without effect in wild-type HEK 293 cells. Neither compd. affected the cytoplasmic  $\text{Ca}^{2+}$  responses elicited by several other G protein-coupled receptors in HEK 293 cells or in bovine parathyroid cells. Significantly, these compds. did not affect responses elicited by the homologous metabotropic glutamate receptors, mGluR1a, mGluR2, or mGluR8. These compds. therefore act selectively on the  $\text{Ca}^{2+}$  receptor. Compds. that mimic or potentiate the effects of extracellular  $\text{Ca}^{2+}$  at the  $\text{Ca}^{2+}$  receptor are termed calcimimetics. The discovery of calcimimetic compds. with potent and selective activity enables a pharmacol. approach to regulating plasma levels of PTH. Calcimimetic compds. could conceivably provide a specific medical therapy for primary hyperparathyroidism.

IT 148717-54-8 148717-56-0, R-NPS 467 148740-52-7  
159149-75-4


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(calcimimetics with potent and selective activity on the parathyroid calcium receptor)

RN 148717-54-8 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 148717-56-0 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148740-52-7 CAPLUS

CN Benzenepropanamine, N-[(1S)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159149-75-4 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1S)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L53 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:151263 CAPLUS

DOCUMENT NUMBER: 130:276915

TITLE: Stimulation of calcitonin secretion by calcium receptor activators: Evaluation using a new, highly sensitive, homologous immunoradiometric assay for rat calcitonin

AUTHOR(S): Lavigne, Jeffrey R.; Zahradnik, Richard J.; Conklin, Rebecca L.; Lambert, Lyssa D.; Logan, Mary A.; Parihar, Ashutosh; Fox, John

CORPORATE SOURCE: Immunotopics, Inc., San Clemente, CA, 92673, USA

SOURCE: Endocrine (1998), 9(3), 293-301

CODEN: EOCRE5; ISSN: 1355-008X

PUBLISHER: Humana Press Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Current rat calcitonin immunoassays use human calcitonin antisera, and suffer from poor sensitivity, long incubation periods, nonspecific interferences, and unreliability. The homologous immunoradiometric assay (IRMA) for rat calcitonin described here overcomes these problems. Overnight incubation yields a detection limit of 0.4 pg/mL, a std. curve that is linear to >1800 pg/mL, and intra- and interassay coeffs. of variation of <7%. Gel filtration chromatog. of rat plasma and rat medullary thyroid carcinoma 44-2 cell media showed that the vast majority of immunoreactivity coeluted with calcitonin std. In 44-2 cells, increasing extracellular Ca<sup>2+</sup> concn. or incubation with the calcimimetic compd. NPS R-467 markedly increased calcitonin secretion. Plasma calcitonin levels were elevated in rats anesthetized with ketamine/xylazine and in conscious rats with chronic renal insufficiency. Calcitonin levels decreased following EGTA-induced hypocalcemia and were



undetectable after thyroparathyroidectomy. In normal conscious rats, plasma calcitonin levels averaged 3-5 pg/mL and increased up to 100-fold following calcium (Ca) infusion or NPS R-467 administration. The assay also quantified calcitonin in plasma of normal and Ca-injected mice. This assay has revealed that plasma calcitonin levels in normal rats are much lower than the detection limits of most existing assays, but can increase by 100-fold on activation of the C-cell Ca<sup>2+</sup> receptor.

IT 148717-56-0, NPS R-467


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(calcitonin secretion stimulation by **calcium receptor** activator NPS R-467 detd. by IRMA)

RN 148717-56-0 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L53 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:113696 CAPLUS

DOCUMENT NUMBER: 128:175690

TITLE: Development of calcimimetics acting at calcium receptors

AUTHOR(S): Nagano, Noburo

CORPORATE SOURCE: Res. Lab. Pharm. Search, Kirin Brewery Ltd., Japan

SOURCE: Igaku no Ayumi (1998), 184(3), 206-207

CODEN: IGAYAY; ISSN: 0039-2359

PUBLISHER: Ishiyaku Shuppan

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Japanese

AB A review, with 4 refs., of the development of calcimimetics acting at calcium receptors e.g. KRN 568 (NPSR 568) for treatment of hypercalcemia from hyperparathyroidism.

IT 148717-54-8, NPS R 568


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(KRN 568; development of calcimimetics acting at **calcium receptors**)

RN 148717-54-8 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



L53 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1997:752835 CAPLUS  
 DOCUMENT NUMBER: 128:30396  
 TITLE: Methods of identifying modulators of perivascular sensory nerve calcium receptors  
 INVENTOR(S): Bukoski, Richard D.; Bian, Ka  
 PATENT ASSIGNEE(S): University of Texas System, USA; Bukoski, Richard D.; Bian, Ka  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742951	A1	19971120	WO 1997-US9097	19970516
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9731467	A1	19971205	AU 1997-31467	19970516
US 6184254	B1	20010206	US 1998-180730	19981113
PRIORITY APPLN. INFO.:			US 1996-18367P	P 19960516
			WO 1997-US9097	W 19970516
AB	Methods are described for identifying compds. which relax or stimulate arterial tension through their action on perivascular sensory nerve calcium receptors. Compds. identified through such methods are useful for the treatment of hypertension, hypotension and other diseases and conditions which alter normal physiol. blood pressure.			
IT	148717-56-0, R-NPS 467 148717-56-0D, analogs 179381-56-7, R-NPS 831 199614-93-2 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (perivascular sensory nerve <b>calcium receptor</b> modulator identification for use as hypotensive and hypertensive agents)			
RN	148717-56-0 CAPLUS			
CN	Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)			


Absolute stereochemistry.



RN 148717-56-0 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179381-56-7 CAPLUS

CN Benzenepropanamine, 2-methoxy-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 199614-93-2 CAPLUS

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-(2-naphthalenyl)ethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L53 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:808795 CAPLUS

DOCUMENT NUMBER: 128:136362

TITLE: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: control of parathyroid cell growth via a calcium receptor

AUTHOR(S): Wada, Michihito; Furuya, Yoshihiro; Sakiyama, Jun-Ichi; Kobayashi, Nami; Miyata, Sonoe; Ishii, Hiromi; Nagano, Nobuo

CORPORATE SOURCE: Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Takasaki, 370-12, Japan

SOURCE: Journal of Clinical Investigation (1997), 100(12), 2977-2983

CODEN: JCINAO; ISSN: 0021-9738

PUBLISHER: Rockefeller University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Parathyroid (PT) cell hyperplasia is a common consequence of chronic renal insufficiency (CRI). NPS R-568 is a phenyl-alkylamine compd. that acts as an agonist (calcimimetic) at the cell surface calcium receptor (CaR). To test the hypothesis that the CaR plays a role in PT hyperplasia in CRI, we tested the effect of NPS R-568 on PT cell proliferation in rats with renal insufficiency. Rats were subjected to 5/6 nephrectomy and then infused i.p. with 5-bromodeoxyuridine (BrdU) to label S-phase cells. Two groups of nephrectomized rats received NPS R-568 by gavage twice daily for 4 d (1.5 and 15 mg/kg body wt.). On day 5, the no. of BrdU-pos. PT cells of vehicle-treated nephrectomized rats was 2.6-fold greater than that of the sham-operated control. Low and high doses of NPS R-568 reduced the no. of BrdU-pos. PT cells by 20 and 50%, resp. No changes in staining, however, were obsd. in ileal epithelial cells (CaR-neg.) or in thyroidal C-cells (CaR-pos.). Furthermore, the effect of NPS R-568 could not be explained by changes in serum 1,25(OH)2D3 or phosphorus. These results indicate that NPS R-568 suppresses PT cell proliferation in rats with renal insufficiency, and lend support to the linkage between the CaR and PT hyperplasia in CRI.

IT 148717-54-8, NPS R 568


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(the calcimimetic compd. NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: control of parathyroid cell growth via a **calcium receptor**)

RN 148717-54-8 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L53 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:768218 CAPLUS

DOCUMENT NUMBER: 128:84597

TITLE: Short-term inhibition of parathyroid hormone secretion

by a calcium-receptor agonist in patients with primary hyperparathyroidism

AUTHOR(S): Silverberg, Shonni J.; Bone, Henry G., III; Marriott, Thomas B.; Locker, Flore G.; Thys-Jacobs, Susan; Dziem, Greg; Kaatz, Scott; Sanguinetti, Elizabeth L.; Bilezikian, John P.

CORPORATE SOURCE: Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, 10032, USA

SOURCE: New England Journal of Medicine (1997), 337(21), 1506-1510  
CODEN: NEJMAG; ISSN: 0028-4793

PUBLISHER: Massachusetts Medical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Surgery is the usual therapy for patients with primary hyperparathyroidism. We investigated the ability of a calcimimetic drug that inhibits parathyroid hormone secretion in vitro to decrease serum parathyroid hormone and calcium concns. in patients with this disorder. We performed a randomized, placebo-controlled study of single oral doses of 4 to 160 mg of the calcium-receptor agonist drug R-568 in 20 postmenopausal women with mild primary hyperparathyroidism. At base line, the mean ( $\pm$ SE) serum calcium concn. was  $10.7 \pm 0.2$  mg per dL ( $2.67 \pm 0.05$  mmol per L). Serum parathyroid hormone and calcium were measured repeatedly after each dose, and safety was assessed. Administration of R-568 resulted in a dose-dependent inhibition of parathyroid hormone secretion. The mean serum parathyroid hormone concn., which was  $77 \pm 11$  pg per mL ( $18.8 \pm 2.7$  pmol per L; normal range, 16 to 65 pg per mL [ $3.9$  to  $15.9$  pmol per L]) at base line, fell by  $26 \pm 8$  percent after 20 mg of R-568 ( $P=0.03$ ), by  $42 \pm 7$  percent after 80 mg ( $P=0.01$ ), and by  $51 \pm 5$  percent after 160 mg ( $P=0.005$ ). Serum ionized calcium concns. fell only after the 160-mg dose, with the decrease closely following the decrease in the serum parathyroid hormone concn. The calcimimetic drug R-568 reduces serum parathyroid hormone and ionized calcium concns. in postmenopausal women with primary hyperparathyroidism.


IT 148717-54-8, R 568  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in humans with primary hyperparathyroidism)

RN 148717-54-8 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L53 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:132773 CAPLUS

DOCUMENT NUMBER: 126:143970

TITLE: Preparation of 1-amino-3,3-diphenylpropanes and related compounds as noncompetitive antagonists of

glutamate receptor operated calcium channels in the central nervous system.

INVENTOR(S): Mueller, Alan L.; Moe, Scott T.; Balandrin, Manuel F.; Delmar, Eric G.; Vanwagenen, Bradford C.; Artman, Linda D.; Barmore, Robert M.; Smith, Daryl L.

PATENT ASSIGNEE(S): Nps Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 313 pp.  
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640097	A1	19961219	WO 1996-US10201	19960607
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6071970	A	20000606	US 1995-485038	19950607
AU 9661125	A1	19961230	AU 1996-61125	19960607
AU 716122	B2	20000217		
EP 831799	A1	19980401	EP 1996-918477	19960607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11506469	T2	19990608	JP 1996-502238	19960607
BR 9609019	A	19990706	BR 1996-9019	19960607
PRIORITY APPLN. INFO.:			US 1995-485038	A 19950607
			US 1993-14813	B2 19930208
			US 1994-194210	B2 19940208
			US 1994-288668	B2 19940809
			WO 1994-US12293	A2 19941026
			WO 1996-US10201	W 19960607
OTHER SOURCE(S):		MARPAT 126:143970		
GI				



AB Title compds. [I; R1, R5 = H, OH, alkyl, hydroxyalkyl, alkoxy, acyloxy, (substituted) Ph, PhCH2, PhO; R2, R6 = H, alkyl, hydroxyalkyl; R2R4 = imino, (CH2)n, (CH2)nNR3(CH2)n; R3 = H, alkyl, HOCH2CH2, alkylphenyl; n = 0-6, only 1 n can = 0; R4 = (substituted) thiofuryl, pyridyl, Ph, PhCH2, PhO, PhS; X = (substituted) Ph, PhCH2, PhO; m = 0-5; Y = N(R3)2; when R1R2 = (CH2)nNR3(CH2)n, then Y = H], were prepd. Thus, di-Et cyanomethylphosphonate was stirred 4 h with NaH in dimethoxyethane; 3,3'-difluorobenzophenone in dimethoxyethane was added and the mixt. was stirred 24 h at room temp. to give the cyanomethyl carbinol, which was hydrogenated to give an aminopropanol which was dehydrated and hydrogenated to give 3,3-bis(3-fluorophenyl)propylamine hydrochloride.

The latter showed anticonvulsant activity against electroshock-induced seizures in mice with ED50 = 20.1 mg/kg i.p.

IT 17480-69-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 1-amino-3,3-diphenylpropanes and related compds. as noncompetitive antagonists of glutamate **receptor** operated **calcium** channels in the central nervous system)

RN 17480-69-2 CAPLUS

CN Benzenemethanamine, .alpha.-methyl-N-(phenylmethyl)-, (.alpha.S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L53 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:200461 CAPLUS

DOCUMENT NUMBER: 122:1057

TITLE: Screening of compounds with potential action against calcium receptors and their use in therapy of disorders of calcium metabolism

INVENTOR(S): Nemeth, Edward F.; Brown, Edward M.; Hebert, Steven C.; Van, Wagenen Bradford C.; Balandrin, Manuel F.; Fuller, Forrest H.; Del Mar, Eric G.

PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc., USA; Nps Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 282 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9418959	A1	19940901	WO 1993-US1642	19930223
W: AT, AU, BB, BG, BR, BY, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9337770	A1	19940914	AU 1993-37770	19930223
EP 637237	A1	19950208	EP 1993-907015	19930223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07506380	T2	19950713	JP 1993-509948	19930223
RU 2146132	C1	20000310	RU 1994-36778	19930223

PRIORITY APPLN. INFO.: WO 1993-US1642 W 19930223

OTHER SOURCE(S): MARPAT 122:1057


AB A method and compn. useful for treating a patient having a disease characterized by an abnormal level of one or more components, the activity of which is regulated or affected by activity of one or more inorg.-ion receptor. Novel compds. useful in these methods and compns. are also provided. The method includes administering to the patient a therapeutically effective amt. of a mol. active at one or more inorg.-ion receptors as an agent or antagonist. Preferably, the mol. is able to act as either a selective agonist or antagonist at a Ca<sup>2+</sup> receptor of one or more but not all cells chosen from the group consisting of parathyroid

cells, bone osteoclasts, juxtaglomerular kidney cells, proximal tubule kidney cells, distal tubule kidney cell, cell of the thick ascending limb of Henle's loop and/or collecting duct, keratinocyte in the epidermis, parafollicular cell in the thyroid (C-cells), intestinal cell, trophoblast in the placenta, platelet, vascular smooth muscle cell, cardiac atrial cell, gastrin and glucagon secreting cells, kidney mesangial cell and mammary cell.

IT 33542-87-9 38235-77-7 88976-53-8  
 125275-99-2 148717-47-9 148717-48-0  
 148717-49-1 148717-53-7 148717-54-8  
 159149-51-6 159149-64-1 159149-75-4  
 159149-76-5 159149-77-6 159149-84-5  
 159149-91-4 159149-92-5 159149-94-7  
 159149-95-8 159149-96-9 159149-97-0  
 159149-98-1 159149-99-2 159150-00-2  
 159150-02-4 159150-03-5 159150-04-6  
 159150-05-7 159150-06-8 159150-07-9  
 159150-08-0 159150-09-1 159150-10-4  
 159150-11-5 159150-12-6 159150-13-7  
 159150-14-8 159150-15-9 159150-16-0  
 159150-17-1 159150-18-2 159150-19-3  
 159150-20-6 159150-21-7 159150-22-8  
 159150-23-9 159150-24-0 159150-25-1  
 159150-26-2 159150-27-3 159150-28-4  
 159150-31-9 159150-32-0 159247-73-1  
 159247-74-2


RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (screening of compds. with potential action against **calcium receptors** and their use in therapy of disorders of **calcium** metab.)

RN 33542-87-9 CAPLUS  
 CN Benzenethanamine, N-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 38235-77-7 CAPLUS  
 CN Benzenemethanamine, .alpha.-methyl-N-(phenylmethyl)-, (.alpha.R)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 88976-53-8 CAPLUS  
 CN Benzenepropanamine, .alpha.-methyl-N-[(1R)-1-phenylethyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 125275-99-2 CAPLUS


CN 1-Naphthalenemethanamine, N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148717-47-9 CAPLUS

CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 148717-48-0 CAPLUS

CN Benzenepropanamine, N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 148717-49-1 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 148717-53-7 CAPLUS


CN Benzenepropanamine, N-[1-(4-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)




Cl

RN 148717-54-8 CAPLUS  
 CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 159149-51-6 CAPLUS  
 CN Benzenebutanamine, N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 159149-64-1 CAPLUS  
 CN Phenol, 4-[2-[(1-phenylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 159149-75-4 CAPLUS  
 CN Benzenepropanamine, 2-chloro-N-[(1S)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159149-76-5 CAPLUS  
CN Benzenepropanamine, 3-fluoro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159149-77-6 CAPLUS  
CN Benzenepropanamine, 3-fluoro-N-[1-(3-methoxyphenyl)ethyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159149-84-5 CAPLUS  
CN Benzenepropanamine, .alpha.-methyl-N-(1-phenylethyl)-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 159149-91-4 CAPLUS  
CN 1-Naphthalenepropanamine, N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159149-92-5 CAPLUS  
CN 2-Naphthalenepropanamine, N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 159149-94-7 CAPLUS  
CN 1-Naphthalenemethanamine, .alpha.-methyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 159149-95-8 CAPLUS  
CN 2-Naphthalenemethanamine, .alpha.-methyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 159149-96-9 CAPLUS


CN 2-Naphthalenemethanamine, N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159149-97-0 CAPLUS

CN Benzenepropanamine, 2-fluoro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159149-98-1 CAPLUS

CN Benzenepropanamine, 3-fluoro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159149-99-2 CAPLUS

CN Benzenepropanamine, 4-fluoro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 159150-00-2 CAPLUS


CN Benzenepropanamine, 4-chloro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159150-02-4 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[1-(3-methoxyphenyl)ethyl]-.alpha.-methyl-,  
(R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 159150-03-5 CAPLUS

CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]-2-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)

RN 159150-04-6 CAPLUS


CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]-3-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)

RN 159150-05-7 CAPLUS

CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]-4-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)

RN 159150-06-8 CAPLUS


CN Benzenepropanamine, 2-chloro-N-[1-(3-methoxyphenyl)ethyl]-.gamma.-methyl-  
(9CI) (CA INDEX NAME)



RN 159150-07-9 CAPLUS

CN Benzenepropanamine, 3-chloro-N-[1-(3-methoxyphenyl)ethyl]-.gamma.-methyl-,  
(R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 159150-08-0 CAPLUS

CN Benzenepropanamine, 3-chloro-N-[1-(3-methoxyphenyl)ethyl]-.gamma.-methyl-,  
(R\*,S\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 159150-09-1 CAPLUS

CN Benzenepropanamine, 4-chloro-N-[1-(3-methoxyphenyl)ethyl]-.gamma.-methyl-,  
(R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 159150-10-4 CAPLUS

CN Benzenepropanamine, 4-chloro-N-[1-(3-methoxyphenyl)ethyl]-.gamma.-methyl-,  
(R\*,S\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 159150-11-5 CAPLUS  
CN Benzenepropanamine, .gamma.-methyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 159150-12-6 CAPLUS  
CN Benzenepropanamine, 4-chloro-N-[1-(2-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 159150-13-7 CAPLUS  
CN Benzenepropanamine, 4-chloro-N-[1-(3-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159150-14-8 CAPLUS  
CN Benzenepropanamine, 4-chloro-N-[1-(4-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)






RN 159150-15-9 CAPLUS  
CN Phenol, 4-[3-[(1-phenylethyl)amino]butyl]-, (R\*,R\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 159150-16-0 CAPLUS  
CN Phenol, 4-[3-[(1-phenylethyl)amino]butyl]-, (R\*,S\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 159150-17-1 CAPLUS  
CN 1-Naphthalenemethanamine, N-[1-(3-methoxyphenyl)ethyl]-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 159150-18-2 CAPLUS  
CN 2-Naphthalenemethanamine, N-[1-(3-methoxyphenyl)ethyl]-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 159150-19-3 CAPLUS

CN 1-Naphthalenemethanamine, N-[3-(2-chlorophenyl)propyl]-.alpha.-methyl-  
(9CI) (CA INDEX NAME)

RN 159150-20-6 CAPLUS


CN Benzenepropanamine, 2-chloro-N-[1-(2-methoxyphenyl)ethyl]- (9CI) (CA  
INDEX NAME)

RN 159150-21-7 CAPLUS


CN Benzenepropanamine, 2-chloro-N-[1-(4-methoxyphenyl)ethyl]- (9CI) (CA  
INDEX NAME)

RN 159150-22-8 CAPLUS


CN Benzenepropanamine, N-[1-(3-ethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159150-23-9 CAPLUS  
CN Benzenepropanamine, 2-chloro-N-[1-(3-ethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 159150-24-0 CAPLUS  
RN 159150-25-1 CAPLUS  
CN Phenol, 4-[1-[[3-(2-chlorophenyl)propyl]amino]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 159150-26-2 CAPLUS  
CN Benzenepropanamine, N-[1-[3-(trifluoromethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 159150-27-3 CAPLUS  
CN Benzenepropanamine, 2-chloro-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 159150-28-4 CAPLUS  
 CN Ethanone, 1-[3-[1-[(3-phenylpropyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 159150-31-9 CAPLUS  
 CN Benzenepropanamine, N-[1-(2,5-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 159150-32-0 CAPLUS  
 CN Benzenepropanamine, N-[1-(3,5-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 159247-73-1 CAPLUS  
 RN 159247-74-2 CAPLUS  
 CN Benzenepropanamine, 3-chloro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




L53 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2002 ACS  
ACCESSION NUMBER: 1993:463054 CAPLUS  
DOCUMENT NUMBER: 119:63054  
TITLE: Calcium receptor-active molecules  
INVENTOR(S): Nemeth, Edward F.; Van Wagenen, Bradford C.;  
Balandrin, Manuel F.  
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 193 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 9  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9304373	A1	19930304	WO 1992-US7175	19920821
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9225889	A1	19930316	AU 1992-25889	19920821
AU 673500	B2	19961114		
JP 06510531	T2	19941124	JP 1992-504650	19920821
JP 2728564	B2	19980318		
EP 657029	A1	19950614	EP 1992-919933	19920821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
JP 09281209	A2	19971031	JP 1996-232165	19920821
JP 09328420	A2	19971222	JP 1996-232130	19920821
JP 11221095	A2	19990817	JP 1998-313631	19920821
JP 3256502	B2	20020212		
RU 2147574	C1	20000420	RU 1994-20394	19920821
JP 2001220356	A2	20010814	JP 2000-394979	19920821
CN 1071333	A	19930428	CN 1992-111580	19920822
CN 1067550	B	20010627		
IL 102917	A1	20001206	IL 1992-102917	19920823
ZA 9206360	A	19930330	ZA 1992-6360	19920824
NO 9400581	A	19940425	NO 1994-581	19940221
AU 9671977	A1	19970220	AU 1996-71977	19961125
AU 711247	B2	19991007		
AU 9931226	A1	19990722	AU 1999-31226	19990524
PRIORITY APPLN. INFO.:			US 1991-749451	A2 19910823
			US 1992-834044	A2 19920211
			US 1992-934161	A2 19920821
			JP 1992-504650	A3 19920821
			JP 1996-232165	A3 19920821
			JP 1998-313631	A3 19920821
			WO 1992-US7175	A 19920821
			US 1993-141248	A 19931022
			US 1994-292827	A 19940819
			AU 1994-80872	A3 19941021

OTHER SOURCE(S): MARPAT 119:63054

GI



I


AB Methods, compns., and compds. are disclosed for treating a patient having a disease characterized by an abnormal level of component(s), the activity of which is regulated or affected by the activity of .gtoreq.1 Ca<sup>2+</sup> receptors. The compds. act as agonists or antagonists of the Ca<sup>2+</sup> receptors, preferably selective to receptors on parathyroid cells, bone osteoclasts, juxtaglomerular kidney cells, proximal tubule kidney cells, keratinocytes, parafollicular thyroid cells, and placental trophoblasts. A method for diagnosis of a disease comprises identifying the no. and/or location of Ca<sup>2+</sup> receptors and making a comparison to that of normal subjects. Methods for identifying useful therapeutic mols. are also disclosed. Structure-function (intracellular Ca<sup>2+</sup>-mobilizing) studies were done on aminoglycosides and other compds. on various cells. Recombinant Ca<sup>2+</sup> receptor protein mRNAs were expressed in *Xenopus* oocytes. Compd. NPS 449 (I) caused a concn.-dependent inhibition of bone resorption with an IC<sub>50</sub> of 10 .mu.M.

IT 148717-48-0

RL: BIOL (Biological study)  
(calcium receptor-active mol.)

RN 148717-48-0 CAPLUS

CN Benzenepropanamine, N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




IT 159149-75-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. of and bovine parathyroid cell calcium receptor activation by)

RN 159149-75-4 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1S)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 148717-54-8P 148717-55-9P 148717-56-0P  
148740-52-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of and bovine parathyroid cell **calcium**  
**receptor** activation by)

RN 148717-54-8 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 148717-55-9 CAPLUS

CN Benzenepropanamine, 3-chloro-N-[1-(3-methoxyphenyl)ethyl]-, (S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 148717-56-0 CAPLUS

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 148740-52-7 CAPLUS

CN Benzenepropanamine, N-[(1S)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




IT 148717-47-9P 148717-49-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of and **calcium receptor** activity of)


RN 148717-47-9 CAPLUS

CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 148717-49-1 CAPLUS

CN Benzenepropanamine, 2-chloro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



L53 ANSWER 18 OF 26 USPATFULL

ACCESSION NUMBER: 2002:19349 USPATFULL

TITLE: Inorganic ion receptor active compounds

INVENTOR(S): Moe, Scott T., Salt Lake City, UT, United States

Van Wagenen, Bradford C., Salt Lake City, UT, United States

DelMar, Eric G., Salt Lake City, UT, United States

Trovato, Richard, Salt Lake City, UT, United States

Balandrin, Manuel F., Sandy, UT, United States

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6342532	B1	20020129
APPLICATION INFO.:	US 1999-415179		19991006 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-846721, filed on 30 Apr 1997, now patented, Pat. No. US 5981599		

NUMBER DATE



-----  
PRIORITY INFORMATION: US 1996-16673P 19960501 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Raymond, Richard L.  
LEGAL REPRESENTATIVE: Warburg, Richard J., Foley & Lardner  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)  
LINE COUNT: 1818

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface calcium receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 199014-37-4P 199014-39-6P 199014-40-9P  
199014-41-0P 199014-42-1P 199014-43-2P  
199014-44-3P 199014-47-6P 199014-48-7P  
199014-51-2P 199014-54-5P 199014-55-6P  
199014-56-7P 199014-57-8P 199014-58-9P  
199014-59-0P 199014-61-4P 199014-63-6P  
199014-64-7P 199014-65-8P 199014-66-9P  
199014-67-0P 199014-68-1P 199014-69-2P  
199014-70-5P 199014-71-6P 199014-78-3P  
199014-80-7P 199014-81-8P 199014-82-9P  
199014-83-0P 199014-84-1P 199014-85-2P  
199014-86-3P 199014-87-4P

(prepn. of arylalkylamine derivs. as inorg. ion receptor-active compds.)

RN 199014-37-4 USPATFULL

CN Benzenemethanamine, N-[(2E)-3-(2-chlorophenyl)-2-propenyl]-3-methoxy-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 199014-39-6 USPATFULL

CN Acetic acid, [3-[(1R)-1-[[3-(2-chlorophenyl)propyl]amino]ethyl]phenoxy]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199014-40-9 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(2E)-3-phenyl-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 199014-41-0 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(2E)-2-methyl-3-phenyl-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 199014-42-1 USPATFULL

CN 1-Naphthalenemethanamine, N-[(2E)-3-(2-methoxyphenyl)-2-propenyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 199014-43-2 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R,2E)-1-methyl-3-[3-(trifluoromethoxy)phenyl]-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



RN 199014-44-3 USPATFULL


CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[3-(2,4,6-trimethylphenyl)propyl]- (9CI) (CA INDEX NAME)



RN 199014-47-6 USPATFULL

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-[(1S,2E)-1-methyl-3-[3-(trifluoromethoxy)phenyl]-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 199014-48-7 USPATFULL


CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-[(1R,2E)-1-methyl-3-[3-(trifluoromethoxy)phenyl]-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 199014-51-2 USPATFULL


CN Benzenepropanamine, 2-chloro-N-[1-(2,3-dichlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 199014-54-5 USPATFULL

CN Benzonitrile, 2-[3-[(1R)-1-(3-methoxyphenyl)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-55-6 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)butyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-56-7 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)-2-methylpropyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-57-8 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)pentyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-58-9 USPATFULL

CN Benzonitrile, 4-[3-[[ (1R)-1-(3-methoxyphenyl)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-59-0 USPATFULL

CN Benzenepropanamine, 2,3-dichloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-61-4 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1S,2E)-1-methyl-3-[3-(trifluoromethoxy)phenyl]-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 199014-63-6 USPATFULL

CN 1-Naphthalenemethanamine, N-[(3,4-dibromophenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-64-7 USPATFULL

CN 1-Naphthalenemethanamine, N-[(4-bromo-3-chlorophenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-65-8 USPATFULL

CN 1-Naphthalenemethanamine, N-[(3-bromo-4-iodophenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-66-9 USPATFULL

CN 1-Naphthalenemethanamine, N-[(3-chloro-4-iodophenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-67-0 USPATFULL

CN 1-Naphthalenemethanamine, N-[(3-iodo-4-methoxyphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-68-1 USPATFULL

CN 1,3-Benzodioxole-4-methanamine, N-[3-(2-chlorophenyl)propyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-69-2 USPATFULL

CN 1,3-Benzodioxole-4-methanamine, N-[3-(2-chlorophenyl)propyl]-.alpha.-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199014-70-5 USPATFULL

CN Benzenepropanamine, 3,4-dichloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 199014-71-6 USPATFULL

CN Benzenepropanamine, 2,4-dichloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 199014-78-3 USPATFULL

CN 1-Naphthalenemethanamine, N-[4-(2,5-dichlorophenyl)butyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-80-7 USPATFULL


CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-iodophenyl)ethyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199014-81-8 USPATFULL  
CN 1-Naphthalenemethanamine, N-[1-(4-iodophenyl)ethyl]-.alpha.-methyl-,  
hydrochloride, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 199014-82-9 USPATFULL  
CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-ethoxy-3-methylphenyl)ethyl]-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199014-83-0 USPATFULL  
CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-ethoxy-3-methylphenyl)ethyl]-  
.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 199014-84-1 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)propyl]-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-85-2 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)propyl]-  
.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 199014-86-3 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(3-bromo-4-methoxyphenyl)ethyl]-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-87-4 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(3-bromo-4-methoxyphenyl)ethyl]-  
.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 179603-37-3

(prepn. of arylalkylamine derivs. as inorg. ion receptor-active compds. with effect on hypertension)

RN 179603-37-3 USPATFULL

CN Benzenepropanamine, 3-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L53 ANSWER 19 OF 26 USPATFULL

ACCESSION NUMBER: 2001:18500 USPATFULL

TITLE: Methods of identifying modulators of perivascular sensory nerve Ca<sup>2+</sup> receptors

INVENTOR(S): Bukoski, Richard D., Galveston, TX, United States  
Bian, Ka, League City, TX, United States

PATENT ASSIGNEE(S): Board of Regents, The University of Texas System,  
Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6184254	B1	20010206
	WO 9742951		19971120
APPLICATION INFO.:	US 1998-180730		19981113 (9)
	WO 1997-US9097		19970516
			19981113 PCT 371 date
			19981113 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-18367P	19960516 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dudash, Diana	

ASSISTANT EXAMINER: Sharareh, Shahnam  
LEGAL REPRESENTATIVE: Fulbright & Jaworski L.L.P.  
NUMBER OF CLAIMS: 6  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 18 Drawing Page(s)  
LINE COUNT: 1812

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of identifying compounds that relax or stimulate arterial tension through their action on perivascular sensory nerve **calcium receptors** are described. Compounds identified through such methods are useful for the treatment of hypertension, hypotension and other diseases and conditions that alter normal physiological blood pressure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 148717-56-0, R-NPS 467 148717-56-0D, analogs


179381-56-7, R-NPS 831 199614-93-2

(perivascular sensory nerve calcium receptor modulator identification for use as hypotensive and hypertensive agents)

RN 148717-56-0 USPATFULL

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148717-56-0 USPATFULL

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 179381-56-7 USPATFULL

CN Benzenepropanamine, 2-methoxy-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 199614-93-2 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R)-1-(2-naphthalenyl)ethyl]-  
, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L53 ANSWER 20 OF 26 USPATFULL

ACCESSION NUMBER: 2000:9954 USPATFULL

TITLE: Compounds active at a novel site on **receptor**  
-operated **calcium** channels useful for  
treatment of neurological disorders and diseasesINVENTOR(S): Mueller, Alan L., Salt Lake City, UT, United States  
Balandrin, Manuel F., Sandy, UT, United States  
VanWagenen, Bradford C., Salt Lake City, UT, United States  
Moe, Scott T., Salt Lake City, UT, United States  
DelMar, Eric G., Salt Lake City, UT, United States  
Artman, Linda D., Salt Lake City, UT, United States  
Barmore, Robert M., Salt Lake City, UT, United States  
Smith, Daryl L., Salt Lake City, UT, United States  
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6017965		20000125
APPLICATION INFO.:	US 1996-763480		19961211 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-663013, filed on 7 Jun 1996 which is a continuation-in-part of Ser. No. US 1995-485038, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. WO 1994-US12293, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-288668, filed on 9 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-194210, filed on 8 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-14813, filed on 8 Feb 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Lyon & Lyon LLP		
NUMBER OF CLAIMS:	35		

EXEMPLARY CLAIM: 1

LINE COUNT: 6207

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 17480-69-2, (S)-N-Benzyl-.alpha.-methylbenzylamine  
(prepn. of aralkylamines as NMDA receptor-ionophore complex antagonists)

RN 17480-69-2 USPATFULL

CN Benzenemethanamine, .alpha.-methyl-N-(phenylmethyl)-, (.alpha.S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L53 ANSWER 21 OF 26 USPATFULL

ACCESSION NUMBER: 1999:142006 USPATFULL

TITLE: Inorganic ion receptor active compounds

INVENTOR(S): Moe, Scott T., Salt Lake City, UT, United States  
Van Wagenen, Bradford C., Salt Lake City, UT, United States

DelMar, Eric G., Salt Lake City, UT, United States

Trovato, Richard, Salt Lake City, UT, United States

Balandrin, Manuel F., Sandy, UT, United States

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981599		19991109
APPLICATION INFO.:	US 1997-846721		19970430 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Lyon & Lyon LLP		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1839		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface **calcium receptor**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 179603-37-3P 199014-37-4P 199014-39-6P




199014-40-9P 199014-41-0P 199014-42-1P  
199014-43-2P 199014-44-3P 199014-47-6P  
199014-48-7P 199014-51-2P 199014-54-5P  
199014-55-6P 199014-56-7P 199014-57-8P  
199014-58-9P 199014-59-0P 199014-61-4P  
199014-63-6P 199014-64-7P 199014-65-8P  
199014-66-9P 199014-67-0P 199014-68-1P  
199014-70-5P 199014-71-6P 199014-78-3P  
199014-80-7P 199014-82-9P 199014-83-0P  
199014-84-1P 199014-85-2P 199014-86-3P  
199014-87-4P 249278-73-7P

(prepn. of aralkylamines as ion receptor ligands)

RN 179603-37-3 USPATFULL

CN Benzenepropanamine, 3-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199014-37-4 USPATFULL

CN Benzenemethanamine, N-[(2E)-3-(2-chlorophenyl)-2-propenyl]-3-methoxy-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 199014-39-6 USPATFULL

CN Acetic acid, [3-[(1R)-1-[[3-(2-chlorophenyl)propyl]amino]ethyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199014-40-9 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(2E)-3-phenyl-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 199014-41-0 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(2E)-2-methyl-3-phenyl-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 199014-42-1 USPATFULL

CN 1-Naphthalenemethanamine, N-[(2E)-3-(2-methoxyphenyl)-2-propenyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 199014-43-2 USPATFULL


CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1R,2E)-1-methyl-3-[3-(trifluoromethoxy)phenyl]-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 199014-44-3 USPATFULL


CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[3-(2,4,6-trimethylphenyl)propyl]- (9CI) (CA INDEX NAME)



RN 199014-47-6 USPATFULL

CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-[(1S,2E)-1-methyl-3-[3-(trifluoromethoxy)phenyl]-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 199014-48-7 USPATFULL


CN Benzenemethanamine, 3-methoxy-.alpha.-methyl-N-[(1R,2E)-1-methyl-3-[3-(trifluoromethoxy)phenyl]-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 199014-51-2 USPATFULL


CN Benzenepropanamine, 2-chloro-N-[1-(2,3-dichlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 199014-54-5 USPATFULL

CN Benzonitrile, 2-[3-[(1R)-1-(3-methoxyphenyl)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-55-6 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)butyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-56-7 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)-2-methylpropyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-57-8 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)pentyl]-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-58-9 USPATFULL

CN Benzonitrile, 4-[3-[(1R)-1-(3-methoxyphenyl)ethyl]amino]propyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 199014-59-0 USPATFULL

CN Benzenepropanamine, 2,3-dichloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 199014-61-4 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[(1S,2E)-1-methyl-3-[3-(trifluoromethoxy)phenyl]-2-propenyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 199014-63-6 USPATFULL

CN 1-Naphthalenemethanamine, N-[(3,4-dibromophenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-64-7 USPATFULL

CN 1-Naphthalenemethanamine, N-[(4-bromo-3-chlorophenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-65-8 USPATFULL

CN 1-Naphthalenemethanamine, N-[(3-bromo-4-iodophenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-66-9 USPATFULL

CN 1-Naphthalenemethanamine, N-[(3-chloro-4-iodophenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-67-0 USPATFULL

CN 1-Naphthalenemethanamine, N-[(3-iodo-4-methoxyphenyl)methyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-68-1 USPATFULL

CN 1,3-Benzodioxole-4-methanamine, N-[3-(2-chlorophenyl)propyl]-.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-70-5 USPATFULL

CN Benzenepropanamine, 3,4-dichloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199014-71-6 USPATFULL

CN Benzenepropanamine, 2,4-dichloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 199014-78-3 USPATFULL

CN 1-Naphthalenemethanamine, N-[4-(2,5-dichlorophenyl)butyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-80-7 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-iodophenyl)ethyl]-.alpha.-methyl-,  
(.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-82-9 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-ethoxy-3-methylphenyl)ethyl]-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-83-0 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-ethoxy-3-methylphenyl)ethyl]-  
.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 199014-84-1 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)propyl]-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-85-2 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(4-methoxy-3-methylphenyl)propyl]-  
.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 199014-86-3 USPATFULL

CN 1-Naphthalenemethanamine, N-[(1R)-1-(3-bromo-4-methoxyphenyl)ethyl]-  
.alpha.-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199014-87-4 USPATFULL


CN 1-Naphthalenemethanamine, N-[(1R)-1-(3-bromo-4-methoxyphenyl)ethyl]-  
.alpha.-methyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 249278-73-7 USPATFULL  
CN 2-Naphthalenemethanamine, .alpha.-methyl-N-[3-(2,4,6-trimethylphenyl)propyl]- (9CI) (CA INDEX NAME)



L53 ANSWER 22 OF 26 USPATFULL  
ACCESSION NUMBER: 1999:121216 USPATFULL  
TITLE: **Calcium receptor**-active molecules  
INVENTOR(S): Brown, Edward M., Milton, MA, United States  
Hebert, Steven C., Wellesley, MA, United States  
Garrett, Jr., James E., Salt Lake City, UT, United States  
PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)  
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5962314		19991005
APPLICATION INFO.:	US 1997-943986		19971003 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-484565, filed on 7 Jun 1995, now patented, Pat. No. US 5763569 which is a continuation-in-part of Ser. No. US 1994-353784, filed on 8 Dec 1994 which is a continuation-in-part of Ser. No. WO 1994-US12117, filed on 21 Oct 1994 Ser. No. Ser. No. US 1994-292827, filed on 19 Aug 1994, now abandoned Ser. No. Ser. No. US 1993-141248, filed on 22 Oct 1993, now abandoned And Ser. No. US 1993-9389, filed on 23 Feb 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ulm, John		
ASSISTANT EXAMINER:	Saoud, Christine		

LEGAL REPRESENTATIVE: Lyon & Lyon LLP  
NUMBER OF CLAIMS: 36  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 111 Drawing Figure(s); 85 Drawing Page(s)  
LINE COUNT: 7882

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is  $\text{Ca}^{2+}$  and the effect is on a cell having a **calcium receptor**; (2) inorganic ion receptor proteins and fragments thereof, preferably **calcium receptor** proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably **calcium receptor** proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion **receptor** proteins, preferably **calcium receptor** protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 148717-48-0

(calcium receptor-active mol.)

RN 148717-48-0 USPATFULL

CN Benzenepropanamine, N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




IT 148717-53-7

(intracellular calcium-mobilizing activity of)

RN 148717-53-7 USPATFULL

CN Benzenepropanamine, N-[1-(4-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)




IT 159149-75-4P

(prepn. of and bovine parathyroid cell calcium receptor activation by)

RN 159149-75-4 USPATFULL

CN Benzenepropanamine, 2-chloro-N-[(1S)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 148717-54-8P 148717-55-9P 148717-56-0P  
148740-52-7P

(prepn. of and bovine parathyroid cell calcium receptor activation by)

RN 148717-54-8 USPATFULL

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 148717-55-9 USPATFULL

CN Benzenepropanamine, 3-chloro-N-[1-(3-methoxyphenyl)ethyl]-, (S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 148717-56-0 USPATFULL


CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148740-52-7 USPATFULL  
 CN Benzenepropanamine, N-[(1S)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 148717-47-9P 148717-49-1P  
 (prepn. of and calcium receptor activity of)  
 RN 148717-47-9 USPATFULL  
 CN Benzenepropanamine, N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 148717-49-1 USPATFULL  
 CN Benzenepropanamine, 2-chloro-N-[1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



L53 ANSWER 23 OF 26 USPATFULL  
 ACCESSION NUMBER: 97:61868 USPATFULL  
 TITLE: Chiral reductions of imines leading to the syntheses of

INVENTOR(S): optically active amines  
VanWagenen, Bradford C., Salt Lake City, UT, United States  
PATENT ASSIGNEE(S): Barmore, Robert M., Salt Lake City, UT, United States  
NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5648541		19970715
APPLICATION INFO.:	US 1995-535469		19950928 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Trask, Britt & Rossa		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	600		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for preparing an R enantiomer of a compound of the formula (I): ##STR1## wherein Ar is 3-methoxyphenyl, 3-chlorophenyl, or 1-naphthyl, and X is independently selected from the group consisting of H, F, Cl, Br, I, phenyl, CF<sub>3</sub>, CF<sub>2</sub>H, CFH<sub>2</sub>, lower alkyl (e.g., Me), O-lower alkyl (e.g., OMe), OCH<sub>2</sub>CF<sub>3</sub>, OH, CN, NO<sub>2</sub>, C(O)-lower alkyl (e.g., C(O)Me), C(O)O-lower alkyl (e.g., C(O)OMe), C(O)NH-lower alkyl (e.g., C(O)NH-Me), C(O)N-lower alkyl (e.g., C(O)NMe), OC(O)-lower alkyl (e.g., OC(O)Me), and NH-C(O)-lower alkyl (e.g., NH-C(O)Me), where "lower alkyl" is selected from a group consisting of 1 to 6 carbon atoms, and m is an integer between 1 and 5, by asymmetrically and enantioselectively reducing an imine with a reducing agent/chiral auxiliary agent complex so as to produce an enantiomeric excess of R enantiomer of the compound of formula (I) over the S enantiomer of the compound of formula (I). The process is especially useful to produce compounds (R)-(+)-N-[1-(3-methoxyphenyl)ethyl]-3-(2-chlorophenyl)propanamine and (R)-(+)-N-[1-(3-methoxyphenyl)ethyl]-3-(phenyl)propanamine. Enantiomeric excess of the R enantiomer over S enantiomer of greater than 65% have been achieved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 148717-54-8P 148717-56-0P

(chiral redns. of arylimines leading to the syntheses of optically active amines)

RN 148717-54-8 USPATFULL

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 148717-56-0 USPATFULL

CN Benzenepropanamine, N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



L53 ANSWER 24 OF 26 USPATFULL

ACCESSION NUMBER: 97:61867 USPATFULL

TITLE: Amine preparation

INVENTOR(S): VanWagenen, Bradford C., Salt Lake City, UT, United States  
Duff, Steven R., De Soto, KS, United States  
Nelson, William A., Lawrence, KS, United States  
D'Ambra, Thomas E., North Greenbush, NY, United States

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5648540		19970715
APPLICATION INFO.:	US 1995-446491		19950522 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-276214, filed on 15 Jul 1994, now patented, Pat. No. US 5504253		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Trask, Britt & Rossa		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	546		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of making (R)-N-[1-(3-methoxyphenyl)ethyl]-3-(2-chlorobenzene)propanamine which involves reducing the appropriate amidyl or iminyl precursor with an appropriate reducing agent. The appropriate amidyl or iminyl precursor is made from a synthesis involving the use of (R)-3-methoxy-.alpha.-methylbenzylamine. A method of condensing a nitrile with a primary or secondary amine to form an imine involves the reaction of a nitrile with diisobutylaluminum hydride; and then reacting the resultant compound with a primary or secondary amine to form the imine. The process is especially useful for producing enantiomerically pure chiral imines, and, ultimately, amines. Typical such imines have the formula: ##STR1## wherein R, R.sub.1, R.sub.2 and R.sub.3 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, aryl and aralkyl.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 148717-54-8P 177172-49-5P

(prepn. of [(methoxyphenyl)ethyl]chlorobenzenepropanamine enantiomer)

RN 148717-54-8 USPATFULL

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 177172-49-5 USPATFULL

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-,  
hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl


IT 177172-50-8P

(prepn. of imines and amines via redn. of nitriles and condensation  
with amines)

RN 177172-50-8 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[3-(3-methylphenyl)-2-propenyl]-  
, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



L53 ANSWER 25 OF 26 USPATFULL

ACCESSION NUMBER: 97:45163 USPATFULL

TITLE: N-((R)-.alpha.-methyl-3-methoxybenzyl)-3-(2-  
chlorobenzene)propanamide

INVENTOR(S): VanWagenen, Bradford C., Salt Lake City, UT, United  
States

Duff, Steven R., De Soto, KS, United States  
Nelson, William A., Lawrence, KS, United States

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United  
States (U.S. corporation)

Searched by Barb O'Bryen, STIC 308-4291

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5633404		19970527
APPLICATION INFO.:	US 1996-639935		19960419 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-446491, filed on 22 May 1995 which is a division of Ser. No. US 1994-276214, filed on 15 Jul 1994, now patented, Pat. No. US 5504253, issued on 2 Apr 1996		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Trask, Britt & Rossa		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	503		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of making ( R)- N-[1-(3-methoxyphenyl)ethyl]-3-(2-chlorobenzene)propanamine which involves reducing the appropriate amidyl or iminyl precursor with an appropriate reducing agent. The appropriate amidyl or iminyl precursor is made from a synthesis involving the use of ( R)-3-methoxy-.alpha.-methylbenzylamine. A method of condensing a nitrile with a primary or secondary amine to form an imine involves the reaction of a nitrile with diisobutylaluminum hydride; and then reacting the resultant compound with a primary or secondary amine to form the imine. The process is especially useful for producing enantiomerically pure chiral imines, and, ultimately, amines. Typical such imines have the formula: ##STR1## wherein R, R.sub.1, R.sub.2 and R.sub.3 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, aryl and aralkyl.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 148717-54-8P 177172-49-5P

(prepn. of [(methoxyphenyl)ethyl]chlorobenzenepropanamine enantiomer)

RN 148717-54-8 USPATFULL

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 177172-49-5 USPATFULL

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

IT 177172-50-8P


(prepn. of imines and amines via redn. of nitriles and condensation with amines)

RN 177172-50-8 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[3-(3-methylphenyl)-2-propenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



L53 ANSWER 26 OF 26 USPATFULL

ACCESSION NUMBER: 96:27362 USPATFULL

TITLE: Amine preparation

INVENTOR(S): VanWagenen, Bradford C., Salt Lake City, UT, United States

D'Ambra, Thomas E., North Greenbush, NY, United States

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5504253		19960402
APPLICATION INFO.:	US 1994-276214		19940715 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Trask, Britt & Rossa		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	581		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of making (R)-N-[1-(3-methoxyphenyl)ethyl]-3-(2-chlorobenzene)propanamine which involves reducing the appropriate amidyl or iminyl precursor with an appropriate reducing agent. The appropriate

amidyl or iminyl precursor is made from a synthesis involving the use of (R)-3-methoxy-.alpha.-methylbenzylamine. A method of condensing a nitrile with a primary or secondary amine to form an imine involves the reaction of a nitrile with diisobutylaluminum hydride; and then reacting the resultant compound with a primary or secondary amine to form the imine. The process is especially useful for producing enantiomerically pure chiral imines, and, ultimately, amines. Typical such imines have the formula: ##STR1## wherein R, R.sub.1, R.sub.2 and R.sub.3 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, aryl and aralkyl.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 148717-54-8P 177172-49-5P

(prepn. of [(methoxyphenyl)ethyl]chlorobenzenepropanamine enantiomer)

RN 148717-54-8 USPATFULL

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 177172-49-5 USPATFULL

CN Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl


IT 177172-50-8P

(prepn. of imines and amines via redn. of nitriles and condensation with amines)

RN 177172-50-8 USPATFULL

CN 1-Naphthalenemethanamine, .alpha.-methyl-N-[3-(3-methylphenyl)-2-propenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



FILE 'HOME' ENTERED AT 15:33:09 ON 24 JUN 2002